<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09817R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Neurological Disorders</subject><subject>Neuroscience</subject><subject>Neuroscience/Neurobiology of Disease and Regeneration</subject><subject>Neurological Disorders/Prion Diseases</subject></subj-group></article-categories><title-group><article-title>Functionally Relevant Domains of the Prion Protein Identified <italic>In Vivo</italic></article-title><alt-title alt-title-type="running-head">PrP Functional Domains <italic>In Vivo</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baumann</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pahnke</surname><given-names>Jens</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Radovanovic</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn2"><sup>&#x000a4;b</sup></xref></contrib><contrib contrib-type="author"><name><surname>R&#x000fc;licke</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bremer</surname><given-names>Juliane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tolnay</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn3"><sup>&#x000a4;c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aguzzi</surname><given-names>Adriano</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department for Cellular Neurology, Hertie Institute of Clinical Brain Research, T&#x000fc;bingen, Germany</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Institute of Laboratory Animal Science and Biomodels Austria, University of Veterinary Medicine Vienna, Vienna, Austria</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Bush</surname><given-names>Ashley I.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Mental Health Research Institute of Victoria, Australia</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>adriano.aguzzi@usz.ch</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FB JP IR AA. Performed the experiments: FB TR JB. Analyzed the data: FB JP JB MT AA. Contributed reagents/materials/analysis tools: IR TR AA. Wrote the paper: FB JP JB MT AA.</p></fn><fn id="fn1" fn-type="current-aff"><label>&#x000a4;a</label><p>Current address: Department of Neurology, Neurodegeneration Research Laboratory (NRL), University of Rostock, Rostock, Germany</p></fn><fn id="fn2" fn-type="current-aff"><label>&#x000a4;b</label><p>Current address: Department of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland</p></fn><fn id="fn3" fn-type="current-aff"><label>&#x000a4;c</label><p>Current address: Institute of Pathology, Department of Neuropathology, University of Basel, Basel, Switzerland</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>9</month><year>2009</year></pub-date><volume>4</volume><issue>9</issue><elocation-id>e6707</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Baumann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p>The prion consists essentially of PrP<sup>Sc</sup>, a misfolded and aggregated conformer of the cellular protein PrP<sup>C</sup>. Whereas PrP<sup>C</sup> deficient mice are clinically healthy, expression of PrP<sup>C</sup> variants lacking its central domain (PrP<sub>&#x00394;CD</sub>), or of the PrP-related protein Dpl, induces lethal neurodegenerative syndromes which are repressed by full-length PrP. Here we tested the structural basis of these syndromes by grafting the amino terminus of PrP<sup>C</sup> (residues 1&#x02013;134), or its central domain (residues 90&#x02013;134), onto Dpl. Further, we constructed a soluble variant of the neurotoxic PrP<sub>&#x00394;CD</sub> mutant that lacks its glycosyl phosphatidyl inositol (GPI) membrane anchor. Each of these modifications abrogated the pathogenicity of Dpl and PrP<sub>&#x00394;CD</sub> in transgenic mice. The PrP-Dpl chimeric molecules, but not anchorless PrP<sub>&#x00394;CD</sub>, ameliorated the disease of mice expressing truncated PrP variants. We conclude that the amino proximal domain of PrP exerts a neurotrophic effect even when grafted onto a distantly related protein, and that GPI-linked membrane anchoring is necessary for both beneficial and deleterious effects of PrP and its variants.</p></abstract><counts><page-count count="13"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>PrP<sup>Sc</sup> is the main constituent of prions <xref ref-type="bibr" rid="pone.0006707-Prusiner1">&#x0005b;1&#x0005d;</xref>, the infectious agents causing transmissible spongiform encephalopathies (TSE). PrP<sup>Sc</sup> is an aggregated and misfolded isoform of the cellular prion protein PrP<sup>C</sup><xref ref-type="bibr" rid="pone.0006707-Oesch1">&#x0005b;2&#x0005d;</xref> which is expressed in a broad range of tissues of most vertebrates <xref ref-type="bibr" rid="pone.0006707-Bendheim1">&#x0005b;3&#x0005d;</xref>. Nascent PrP<sup>C</sup> is exported to the lumen of the endoplasmic reticulum, deprived of its amino terminal signal sequence, glycosylated at two asparagine residues, and endowed with a GPI moiety which anchors it to the outer cell surface. Ablation of the <italic>Prnp</italic> gene, which encodes PrP<sup>C</sup>, abrogates prion replication <xref ref-type="bibr" rid="pone.0006707-Beler1">&#x0005b;4&#x0005d;</xref> and toxicity <xref ref-type="bibr" rid="pone.0006707-Brandner1">&#x0005b;5&#x0005d;</xref>. <italic>Prnp</italic><sup>o/o</sup> mice enjoy a normal life expectancy <xref ref-type="bibr" rid="pone.0006707-Beler2">&#x0005b;6&#x0005d;</xref>, but suffer from subtle neurological phenotypes <xref ref-type="bibr" rid="pone.0006707-Nazor1">&#x0005b;7&#x0005d;</xref> whose molecular basis has remained elusive <xref ref-type="bibr" rid="pone.0006707-Aguzzi1">&#x0005b;8&#x0005d;</xref>.</p><p>Transgenic expression of amino proximally truncated PrP<sup>C</sup> mutants (PrP<sub>&#x00394;CD</sub>, PrP<sub>&#x00394;E</sub> and PrP<sub>&#x00394;F</sub>, henceforth collectively termed &#x00394;PrP) causes early-onset ataxia and white-matter degeneration (<xref ref-type="fig" rid="pone-0006707-g001">Fig. 1A</xref>). Toxicity appears to correlate with partial or complete deletions of the conserved PrP central domain (CD, residues 94&#x02013;134) <xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Li1">&#x0005b;11&#x0005d;</xref> which bridges the flexible amino proximal tail and the globular carboxy proximal domain <xref ref-type="bibr" rid="pone.0006707-Wuthrich1">&#x0005b;12&#x0005d;</xref>.</p><fig id="pone-0006707-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.g001</object-id><label>Figure 1</label><caption><title>PrP and Dpl genes, chimeric constructs, and transgenic mice.</title><p>(A) Schematic drawing of the deletion mutants utilized for generation of transgenic mice, and comparison to full-length wild-type PrP<sup>C</sup> and Dpl. (B) Comparison of the structures of the globular carboxy terminal domains of murine PrP (left) and Dpl (right) (C&#x02013;F) Hydrophobicity plots of wild-type murine PrP (C); wild-type murine Dpl (D); PrP_Dpl (E) and CD_Dpl (F). PrP and Dpl sequences are drawn in blue and red, respectively. SP: secretory signal peptide, cleaved after sorting of the precursor to endoplasmic reticulum. repeats: five repeats of eight amino acids. CC: charge cluster. HC: hydrophobic core. CD: central domain. H1&#x02013;3: &#x003b1;-helix 1, 2, 3 of the globular carboxy proximal domain. MA: membrane anchor of precursor protein, replaced during maturation with glycosyl phosphatidyl inositol anchor. The symbol &#x02592; indicates the epitopes recognized by the monoclonal mouse antibodies POM1, POM3, POM11, and E2.</p></caption><graphic xlink:href="pone.0006707.g001"/></fig><p>Another neurotoxic phenotype was detected in compound-heterozygous <italic>Prnp</italic><sup>o/ZHII</sup> mice and in homozygous <italic>Prnp</italic><sup>ZHII/ZHII</sup> mice <xref ref-type="bibr" rid="pone.0006707-Rossi1">&#x0005b;13&#x0005d;</xref> whose <italic>Prnp</italic><sup>ZHII</sup> allele leads to ectopic expression of the PrP<sup>C</sup>-related protein Dpl <xref ref-type="bibr" rid="pone.0006707-Moore1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Weissmann1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Sakaguchi1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Nishida1">&#x0005b;17&#x0005d;</xref>. Neuronal expression of Dpl in Tg(Dpl) or Tg(N-Dpl) mice induces ataxia within 40&#x02013;60 days <xref ref-type="bibr" rid="pone.0006707-Yamaguchi1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Moore2">&#x0005b;19&#x0005d;</xref>. Despite 80&#x00025; amino acid sequence dissimilarities <xref ref-type="bibr" rid="pone.0006707-Moore1">&#x0005b;14&#x0005d;</xref>, the overall 3D structure of Dpl is similar to that of PrP<sup>C</sup> (<xref ref-type="fig" rid="pone-0006707-g001">Fig. 1B</xref>) and includes an unstructured amino proximal tail, a globular three-helix domain <xref ref-type="bibr" rid="pone.0006707-Luhrs1">&#x0005b;20&#x0005d;</xref>, and a GPI anchor. However, Dpl is physiologically not expressed in the adult nervous system <xref ref-type="bibr" rid="pone.0006707-Behrens1">&#x0005b;21&#x0005d;</xref> and, importantly, lacks any sequences comparable to the CD. Therefore, Dpl resembles the neurotoxic &#x00394;PrP mutants. What is more, the toxicity of both Dpl and &#x00394;PrP is counteracted by co-expression of full-length PrP<sup>C</sup><xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Yamaguchi1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Moore3">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Li2">&#x0005b;23&#x0005d;</xref>, implying that it exploits common molecular pathways.</p><p>We reported previously that the removal of just the CD domain confers dramatic neurotoxicity to PrP. This suggests that the toxicity of Dpl may also result from the absence of a CD-like domain. Here, we tested this hypothesis by transgenic expression of two chimeric proteins, PrP_Dpl (residues 1&#x02013;65 of Dpl replaced by residues 1&#x02013;133 of PrP) and CD_Dpl (residues 90&#x02013;133 of PrP inserted between residues 65 and 66 of Dpl). Transgenic mice expressing these proteins did not develop any clinical phenotypes. Additionally, coexpression of PrP_Dpl or of CD_Dpl ameliorated the clinical syndromes and prolonged the life expectancy of mice expressing neurotoxic &#x00394;PrP mutants, in agreement with a previous report <xref ref-type="bibr" rid="pone.0006707-Yoshikawa1">&#x0005b;24&#x0005d;</xref>. Since PrP is thought to be involved in signal transduction, we tested whether the toxicity of CD-deficient PrP mutants (PrP<sub>&#x00394;CD</sub>) may require localization to membrane lipid rafts. Indeed, removal of the GPI addition signal from PrP<sub>&#x00394;CD</sub> prevents its neurotoxic effects.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Transgenic mice expressing chimeric PrP-Dpl proteins and PrP<sub>&#x00394;CDs</sub></title><p>All chimeric mutants of Dpl and PrP described here are based on the &#x02018;half-genomic&#x02019; pPrPHG backbone <xref ref-type="bibr" rid="pone.0006707-Fischer1">&#x0005b;25&#x0005d;</xref> whose expression pattern has been recently studied in detail <xref ref-type="bibr" rid="pone.0006707-Karapetyan1">&#x0005b;26&#x0005d;</xref>. This construct contains a redacted murine <italic>Prnp</italic> gene which lacks intron #2 and is flanked by 6 and 2.2 kb of 5&#x02032; and 3&#x02032; genomic regions, respectively. Neuronal expression of Dpl leads to ataxia, neuronal loss and demyelinating neuropathy <xref ref-type="bibr" rid="pone.0006707-Nishida1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Yamaguchi1">&#x0005b;18&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-Moore2">&#x0005b;19&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-Moore3">&#x0005b;&#x0005b;22&#x0005d;&#x0005d;</xref> while most of the toxicity of truncated PrP can be assigned to the lack of the central domain CD (residues 94&#x02013;134) <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. If the absence of a CD-like domain were responsible for its toxicity, addition of domains containing the CD region of PrP might detoxify Dpl.</p><p>We constructed CD_Dpl, a chimeric fusion protein consisting of codons 90&#x02013;133 of mouse <italic>Prnp</italic> inserted between codons 65 and 66 of <italic>Prnd</italic> (<xref ref-type="fig" rid="pone-0006707-g001">Fig. 1A, F</xref>). This particular insertional position was chosen because hydrophobicity comparisons suggested that the resulting chimeric protein would resemble wild-type PrP (<xref ref-type="fig" rid="pone-0006707-g001">Fig. 1C&#x02013;D</xref>). In a second construct termed PrP_Dpl, the amino terminus of PrP comprising codons 1&#x02013;133 was fused to the carboxy terminus of Dpl comprising codons 66&#x02013;179 (<xref ref-type="fig" rid="pone-0006707-g001">Fig. 1A</xref>; E). Pronuclear injection was performed into <italic>Prnp</italic><sup>&#x0002b;/o</sup> zygotes resulting from a cross between <italic>Prnp</italic><sup>o/o</sup> and wild-type (wt) C57BL/6N mice giving rise to transgenic founders on a <italic>Prnp</italic><sup>&#x0002b;/o</sup> background (henceforth termed PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e001.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e002.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e003.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e004.jpg" mimetype="image"/></inline-formula> with superscripts defining the <italic>Prnp</italic> allelic status and subscripts denoting the respective hemizygous transgenes).</p><p>PrP and Dpl are tethered to the cell membrane by a C-terminal GPI anchor. PrP has been proposed to act as a signal transducer acting on various signaling pathways <xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-MouilletRichard1">&#x0005b;27&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-Chen1">&#x0005b;28&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-Santuccione1">&#x0005b;29&#x0005d;</xref><xref ref-type="bibr" rid="pone.0006707-Toni1">&#x0005b;&#x0005b;30&#x0005d;&#x0005d;</xref>, and in this context it was speculated that PrP<sub>&#x00394;CD</sub> toxicity may require membrane localization. To test this hypothesis, we introduced two point mutations at codons 232 and 233 (original mouse numbering) of the half-genomic construct PrP<sub>&#x00394;CD</sub><xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, resulting in two in-frame stop codons. This prevents the translation of the carboxy terminal hydrophobic membrane anchoring domain of the precursor protein (see <xref ref-type="fig" rid="pone-0006707-g001">Fig. 1A</xref>), resulting in a secreted PrP mutant termed PrP<sub>&#x00394;CDs</sub>. Because of the possible toxicity of the transgene, pronuclear injection was performed into hybrid B6D2F1 <italic>Prnp</italic><sup>&#x0002b;/&#x0002b;</sup> zygotes to generate PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e005.jpg" mimetype="image"/></inline-formula> (shorthand as above) transgenic mice. The latter mice were predicted to be viable due to the coexpression of wild-type PrP.</p><p>CD_Dpl founder mice #1070, #1071 and #1073, as well as PrP_Dpl founder mice #1023, #1024, #1025 and #1026 and PrP<sub>&#x00394;CDs</sub> founder mice #36, #37, #38, #39, #40, #41, #42, #43 all exhibited undistorted Mendelian transmission of the transgene when backcrossed to <italic>Prnp</italic><sup>o/o</sup> mice. Transgenic lines were named according to the serial number of their founders. F<sub>2</sub> generation mice were screened for transgenic integration and expression. One CD_Dpl line (<italic>Tg1071</italic>), two PrP_Dpl lines (<italic>Tg1025</italic> and <italic>Tg1026</italic>) and two PrP<sub>&#x00394;CDs</sub> lines (<italic>Tg40</italic> and <italic>Tg42</italic>) displayed easily detectable protein expression and were chosen for further analysis (<xref ref-type="table" rid="pone-0006707-t001">Table 1</xref>, <xref ref-type="supplementary-material" rid="pone.0006707.s001">Fig. S1</xref>, <xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A&#x02013;C</xref>). Quantitative PCR using primers complementary to the common CD sequence (CD_Dpl and PrP_Dpl) or to the 3&#x02032;-end of the coding region (PrP<sub>&#x00394;CDs</sub>) showed high copy numbers per genome in all transgenic lines, resulting in higher mRNA levels for <italic>Prnp</italic> in wt mice or Dpl in <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (<xref ref-type="table" rid="pone-0006707-t001">Table 1</xref>, <xref ref-type="supplementary-material" rid="pone.0006707.s001">Fig. S1</xref>).</p><fig id="pone-0006707-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.g002</object-id><label>Figure 2</label><caption><title>Expression and localization of transgenic proteins.</title><p>(A) Similar glycosylation patterns of PrP<sup>C</sup>, PrP_Dpl, CD_Dpl and Dpl. Brain homogenates were subjected to PNGase F treatment as indicated, and analyzed by Western blotting using anti-PrP mouse monoclonal antibody POM3 (upper panel) or anti-Dpl mouse monoclonal antibody E2 (lower panel). The spurious band at 20&#x02013;25 kDa in the 1<sup>st</sup> lane of the lower panel may indicate incomplete deglycosylation of Dpl. (B) The glycosylation patterns of full-length PrP, PrP<sub>&#x00394;CD</sub> and PrP<sub>&#x00394;CDs</sub> are similar. PNGase-treated brain homogenates were analyzed by Western blotting using anti-PrP mouse monoclonal antibody POM11. (C) protein levels in brain extract of transgenic mice compared to PrP in BL/6 mice (filled black columns and left ordinate) and compared Dpl in Nagasaki mice (open columns and right y-axis) using either PrP specific anti bodies POM11 or POM 3 or Dpl specific antibody E2 for western blot. Each column represents the average of 3 mice. (D) Detergent-resistant membrane (DRM) preparations from transgenic mouse brains were separated by density gradient centrifugation and analyzed by Western blotting with monoclonal antibody POM3. Significant amounts of PrP<sup>C</sup>, PrP_Dpl, and CD_Dpl buoyed similarly to flotillin (48 kDa) confirming localization within DRMs. Non-buoyant fractions may indicate raft disruption or may represent immature protein fractions. (E) Density gradient DRM preparations of wild-type and anchorless PrP (PrP<sub>s</sub>), PrP<sub>&#x00394;CD</sub> and PrP<sub>&#x00394;CDs</sub> transgenic brains analyzed after deglycosylation with PNGase F with monoclonal antibody POM1. PrP and PrP<sub>&#x00394;CD</sub> buoyed similarly to flotillin, whereas PrP<sub>s</sub> and PrP<sub>&#x00394;CDs</sub> (lower band in fraction 13, arrowhead) were never DRM-associated irrespectively of the presence or absence of wild-type PrP (&#x0002a;). (F) Plasma concentration of prion protein variants. Plasma from wild-type <italic>Prnp</italic><sup>&#x0002b;/&#x0002b;</sup>; <italic>Prnp</italic><sup>&#x0002b;/o</sup>; <italic>Prnp</italic><sup>o/o</sup>; PrP<sub>&#x00394;CD</sub> (<italic>Tg1046</italic>), PrP<sub>&#x00394;CDs</sub> (<italic>Tg40; Tg42</italic>) and anchorless PrP<sub>s</sub> (<italic>Tg44</italic>) mice was studied by ELISA with POM antibodies. PrP plasma levels were vastly elevated in all transgenic mice expressing anchorless versions of PrP. (G&#x02013;N) Cerebellar sections immunostained with antibodies directed against PrP (POM3) (G&#x02013;J) and Dpl (K&#x02013;N). POM3 immunoreactivity was seen in the molecular and granule cell layers of wt (G), PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e006.jpg" mimetype="image"/></inline-formula> (H) and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e007.jpg" mimetype="image"/></inline-formula> (I) mice but was absent, as expected, from <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> cerebella (J). Cerebellar molecular and granule cell layers are immunostained with anti-Dpl antibody in PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e008.jpg" mimetype="image"/></inline-formula> (L) PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e009.jpg" mimetype="image"/></inline-formula> (M) and <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (N). No Dpl staining was observed in wt mice (K) Scale bar 100 &#x000b5;m.</p></caption><graphic xlink:href="pone.0006707.g002"/></fig><table-wrap id="pone-0006707-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.t001</object-id><label>Table 1</label><caption><title>Characterization of transgenic mice.</title></caption><alternatives><graphic id="pone-0006707-t001-1" xlink:href="pone.0006707.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Construct</td><td align="left" rowspan="1" colspan="1">Deletion</td><td align="left" rowspan="1" colspan="1">Transgenic copy numbers</td><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Mouse line</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PrP<sup>wt</sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1<sup>&#x0002b;</sup>/0<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">1<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1">Bl6 WT</td></tr><tr><td align="left" rowspan="1" colspan="1">PrP<sub>&#x00394;F</sub></td><td align="left" rowspan="1" colspan="1">&#x00394;32&#x02013;134</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">2<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1">2<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1"><italic>TgF35</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">PrP<sub>&#x00394;CD</sub></td><td align="left" rowspan="1" colspan="1">&#x00394;94&#x02013;134</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1">0.2<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg1046</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">PrP<sub>&#x00394;CDs</sub></td><td align="left" rowspan="1" colspan="1">&#x00394;94&#x02013;134 &#x00394;231&#x02013;254</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3.5<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1">0.3<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg40</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">PrP<sub>&#x00394;CDs</sub></td><td align="left" rowspan="1" colspan="1">&#x00394;94&#x02013;134 &#x00394;231&#x02013;254</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1">0.3<sup>&#x0002b;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg42</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Dpl</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0<sup>&#x0002b;</sup>/1<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">1<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">Bl6 Nagasaki</td></tr><tr><td align="left" rowspan="1" colspan="1">CD_Dpl</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">1.6<sup>&#x0002b;</sup>/22<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">5<sup>&#x0002b;</sup>/1<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg1071</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">PrP_Dpl</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">4<sup>&#x0002b;</sup>/120<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">2<sup>&#x0002b;</sup>/0.2<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg1025</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">PrP_Dpl</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">220</td><td align="left" rowspan="1" colspan="1">7<sup>&#x0002b;</sup>/180<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">3<sup>&#x0002b;</sup>/0.4<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1"><italic>Tg1026</italic></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>PrP mRNA and protein levels are expressed relatively to wild-type mice (<sup>&#x0002b;</sup>) or, in the case of <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice, relatively to Dpl expression (<sup>&#x0002a;</sup>).</p></fn></table-wrap-foot></table-wrap><p>Western blots with monoclonal antibody POM3, whose linear epitope was mapped to amino acid residues 95&#x02013;105 of PrP<sup>C</sup><xref ref-type="bibr" rid="pone.0006707-Polymenidou1">&#x0005b;31&#x0005d;</xref>, revealed significant expression of PrP_Dpl chimeras (2&#x02013;3 times higher compared to PrP in wt C57BL/6 mice) and of CD_Dpl (5-fold higher than wt C57BL/6 mice; <xref ref-type="table" rid="pone-0006707-t001">Table 1</xref> and <xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A, C</xref>). The expression of CD_Dpl was similar to that of Dpl in <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice, whereas PrP_Dpl levels were lower (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A, C</xref>). The microanatomical distribution of the transgenic proteins resembled that of PrP<sup>C</sup> (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2G&#x02013;N</xref>). Western blots of brain homogenates with monoclonal antibody POM11, whose epitope encompasses amino acids 64&#x02013;72 and 72&#x02013;80 <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Polymenidou1">&#x0005b;31&#x0005d;</xref>, revealed significant expression of PrP<sub>&#x00394;CDs</sub> (20&#x02013;30&#x00025; of wt C57BL/6 mice, <xref ref-type="table" rid="pone-0006707-t001">Table 1</xref> and <xref ref-type="fig" rid="pone-0006707-g002">Fig. 2B&#x02013;C</xref>).</p><p>The levels of PrP<sub>&#x00394;CDs</sub> in brains of both transgenic lines <italic>Tg40</italic> and <italic>Tg42</italic> was similar to that of <italic>Tg1046</italic> PrP<sub>&#x00394;CD</sub><xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2B, C</xref>) and paralleled the measured amount of mRNA (<xref ref-type="supplementary-material" rid="pone.0006707.s001">Fig. S1</xref>). PrP<sub>&#x00394;CDs</sub> showed a higher electrophoretic mobility than PrP<sub>&#x00394;CD</sub> by 2&#x02013;3 kDa, indicative of the missing GPI anchor.</p><p>Upon PNGase-F treatment, the complex banding pattern of PrP_Dpl, CD_Dpl, PrP<sup>C</sup>, PrP<sub>&#x00394;CDs</sub>, and PrP<sub>&#x00394;CD</sub> was reduced to one single band of lower molecular weight (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A&#x02013;B</xref>), suggesting that these proteins were N-glycosylated. The strong reducing conditions prior to PNGase-F treatment prevented recognition of Dpl by anti-Dpl antibody (data not shown). suggesting that this antibody recognizes a discontinuous C-terminal epitope destroyed by reduction of the two disulfide bridges of Dpl. Milder pretreatment resulted in partial deglycosylation of Dpl (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A</xref>, arrowhead); under these conditions CD_Dpl extracts gave rise to two additional bands, which may indicate posttranslational cleavage (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A</xref>, arrowhead). PrP_Dpl extracts did not show this phenomenon.</p><p>We then prepared detergent-resistant membranes (DRMs) from wild-type, PrP_Dpl and CD_Dpl, (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2D</xref>), PrP<sub>&#x00394;CDs,</sub> anchorless PrP<sub>s</sub>, and PrP<sub>&#x00394;CD</sub> brains (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2E</xref>) in the presence or absence of PrP<sup>C</sup>. The buoyancy of PrP_Dpl, CD_Dpl, and PrP<sub>&#x00394;CD</sub> was similar to that of PrP<sup>C</sup> and flotillin (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2D&#x02013;E</xref>), suggesting that they all reside in similar membrane microdomains. Therefore, most aspects of PrP_Dpl and CD_Dpl biogenesis appear to be similar to those of PrP<sup>C</sup>. In contrast, both PrP<sub>&#x00394;CDs</sub> and PrP<sub>s</sub> displayed less buoyancy, suggesting no association with rafts in agreement with their biogenesis as soluble proteins. We then prepared DRMs from <italic>Tg42</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e010.jpg" mimetype="image"/></inline-formula> mice coexpressing PrP<sup>C</sup> and PrP<sub>&#x00394;CDs</sub>. Fractions were deglycosylated with PNGase F prior to western blotting. This experiment revealed that coexpression of wild-type PrP fails to recruit PrP<sub>&#x00394;CDs</sub> to DRMs. Upon pretreatment with phosphatidylinositol-specific phospholipase C (PI-PLC) the buoyancy of the GPI-anchored PrP variants became similar to that of their anchorless counterparts (<xref ref-type="supplementary-material" rid="pone.0006707.s002">Fig. S2</xref>).</p><p>Finally, we determined the serum PrP concentration in PrP<sup>wt</sup>, PrP<sub>&#x00394;CD</sub>, and PrP<sub>&#x00394;CDs</sub> mice, as well as in GPI-<italic>Tg44</italic> mice expressing anchorless full-length PrP<sub>s</sub><xref ref-type="bibr" rid="pone.0006707-Chesebro1">&#x0005b;32&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2F</xref>). Despite similar PrP levels in brain homogenates, mice expressing anchorless versions of PrP (PrP<sub>s</sub> or PrP<sub>&#x00394;CDs</sub>) displayed up to 4-fold higher serum levels. Therefore, PrP<sub>&#x00394;CDs</sub> underwent normal maturation and glycosylation but was predominantly secreted, similarly to PrP<sub>s</sub>.</p></sec><sec id="s2b"><title>Phenotypes of mice expressing PrP-Dpl chimeric proteins</title><p>All transgenic lines (<italic>Tg1025; Tg1026; Tg1071</italic>) were maintained in the <italic>Prnp</italic><sup>&#x0002b;/o</sup> or <italic>Prnp</italic><sup>o/o</sup> allelotype (PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e011.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e012.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e013.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e014.jpg" mimetype="image"/></inline-formula>), and monitored using a four-degree clinical score <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. It has previously been shown that onset and development of disease correlate with expression levels of Dpl. Tg(Dpl)28272/ZrchI and (TgN-Dpl)32 mice, which express high amounts of Dpl, survived only 32 and 60 days respectively <xref ref-type="bibr" rid="pone.0006707-Yamaguchi1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Moore2">&#x0005b;19&#x0005d;</xref> whereas mice expressing lower Dpl levels, such as <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice <xref ref-type="bibr" rid="pone.0006707-Sakaguchi1">&#x0005b;16&#x0005d;</xref>, showed progressive symptoms of ataxia and were euthanized according to clinical scoring at &#x02265;70 weeks of age. Instead, none of the PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e015.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e016.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e017.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e018.jpg" mimetype="image"/></inline-formula> mice showed abnormal behavior even at &#x0003e;100 weeks of age, and most of them died at 26&#x02013;35 months of age (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3A</xref>). This suggests that the presence of amino terminal domains of PrP reduces the toxicity of Dpl.</p><fig id="pone-0006707-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.g003</object-id><label>Figure 3</label><caption><title>Survival and histological phenotype of PrP/Dpl chimeric mice.</title><p>(A) Survival of transgenic mice. The longevity of both PrP_Dpl and CD_Dpl mice was unaffected by their endogenous <italic>Prnp</italic> status. All mice survived longer than Nagasaki mice and did not develop clinically apparent pathologies. Each line represents data derived from &#x02265;8 individuals. (B&#x02013;R) Histopathological changes in 60 week old wt (1<sup>st</sup> column from left), PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e019.jpg" mimetype="image"/></inline-formula><italic>Tg1026</italic> (2<sup>nd</sup> column), PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e020.jpg" mimetype="image"/></inline-formula><italic>Tg1071</italic> (3<sup>rd</sup> column), and PrP<sup>Ngsk/Ngsk</sup> mice (4<sup>th</sup> column). Panels B&#x02013;I represent GFAP immunostains of the cerebellum (1<sup>st</sup> row) and of the corpus callosum (2<sup>nd</sup> row), whereas panels J&#x02013;M depict paraphenylene diamine-stained semithin sections of the mid-thoracic spinal cord (3<sup>rd</sup> row) and sciatic nerve (4<sup>th</sup> row). PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e021.jpg" mimetype="image"/></inline-formula> mice showed mild cerebellar astrogliosis (D), whereas PrP<sup>Ngsk/Ngsk</sup> mice had additional vacuolar white matter changes (arrows) and Purkinje cell loss (E). No pathological changes were seen in <italic>Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e022.jpg" mimetype="image"/></inline-formula> (C), <italic>Tg1025</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e023.jpg" mimetype="image"/></inline-formula> (not shown) and wt mice (B). Vacuolar white matter pathology and astrogliosis in the corpus callosum of PrP<sup>Ngsk/Ngsk</sup> mice (I) but not in wt (F), PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e024.jpg" mimetype="image"/></inline-formula> (G) and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e025.jpg" mimetype="image"/></inline-formula> mice (H). Semithin sections revealed coarse vacuolar degeneration of myelinated fiber tracts in PrP<sup>Ngsk/Ngsk</sup> mice (M, R), whereas no such changes were observed in wt (J, O), PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e026.jpg" mimetype="image"/></inline-formula> (K, P) and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e027.jpg" mimetype="image"/></inline-formula> mice (L, Q). Arrows: areas with axonal loss; arrowheads: axons with degenerated myelin sheaths (M, R). Scale bars: 100 &#x000b5;m in panels B&#x02013;I; 25 &#x000b5;m in panels J&#x02013;R.</p></caption><graphic xlink:href="pone.0006707.g003"/></fig></sec><sec id="s2c"><title>Phenotypes of mice expressing anchorless PrP<sub>&#x00394;CDs</sub> proteins</title><p>Transgenic lines <italic>Tg40</italic> and <italic>Tg42</italic>, henceforth termed PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e028.jpg" mimetype="image"/></inline-formula>, and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e029.jpg" mimetype="image"/></inline-formula>, were monitored using the same clinical score as with Dpl-PrP chimeric mice. Onset and development of disease caused by PrP<sub>&#x00394;CD</sub> correlated inversely with expression levels of the transgene and was ameliorated by coexpression of PrP<sup>C</sup>. Mice expressing high amounts of PrP<sub>&#x00394;CD</sub> survived 35 (<italic>Tg1050</italic>) or 80 days (<italic>Tg1047</italic>) in a PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e030.jpg" mimetype="image"/></inline-formula> genotype whereas <italic>Tg1046 mice</italic>, which express less PrP<sub>&#x00394;CD</sub> only developed pathology in the absence of PrP<sup>C</sup> and reached an age of 26 days <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. Despite higher total expression levels in PrP<sub>&#x00394;CDs</sub> than in PrP<sub>&#x00394;CD</sub>, even after &#x0003e;60 weeks none of the PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e031.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e032.jpg" mimetype="image"/></inline-formula>, and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e033.jpg" mimetype="image"/></inline-formula> from both transgenic lines <italic>Tg40</italic> and <italic>Tg42</italic> showed abnormal behavior, and most of them died at a similarly advanced age as wt mice (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4A</xref>). Therefore, removal of the membrane anchor prevents the toxicity caused by deletion of the central domain (CD) of PrP<sup>C</sup>.</p><fig id="pone-0006707-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.g004</object-id><label>Figure 4</label><caption><title>Survival and histological phenotype of transgenic mice expressing PrP<sub>&#x00394;CDs.</sub></title><p>(A) Survival of compound transgenic mice. Survival curves of mice expressing <italic>Tg1046</italic> PrP<sub>&#x00394;CD</sub>, <italic>Tg42</italic> PrP<sub>&#x00394;CDs</sub> or PrP<sub>&#x00394;CD</sub> and PrP<sub>&#x00394;CDs</sub> (<italic>Tg1046&#x000d7;Tg42</italic>), in the presence or absence of full-length PrP<sup>C</sup>. Each line comprises the number of individuals indicated in <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>. (B&#x02013;I) Histopathological changes in 23 days old wt (B, F), <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e034.jpg" mimetype="image"/></inline-formula>, (C, G), and terminal <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e035.jpg" mimetype="image"/></inline-formula> mice (D, H) and <italic>Prnp</italic><sup>o/o</sup> mice (E, I); B&#x02013;E are GFAP immunostains of cerebellum, F&#x02013;I are transverse semithin sections of sciatic nerves. Severe astrogliosis and vacuolar changes (arrows) are observed in cerebellar white matter of <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e036.jpg" mimetype="image"/></inline-formula> mice (D) as described <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. No pathological changes are seen in <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e037.jpg" mimetype="image"/></inline-formula> (C) wt (B) and <italic>Prnp</italic><sup>o/o</sup> mice (E). Transverse semithin sections of the sciatic nerve (F&#x02013;I) reveal mild axonal loss (arrows) and coarse vacuolar degeneration in myelinated fiber tracts in <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e038.jpg" mimetype="image"/></inline-formula> mice (H) while no such changes are observed in wt (F), <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e039.jpg" mimetype="image"/></inline-formula> (G) and <italic>Prnp</italic><sup>o/o</sup> mice (I). White arrowheads: axons with degenerated myelin sheaths. Scale bars: 200 &#x000b5;m (B&#x02013;E) or 20 &#x000b5;m (F&#x02013;I).</p></caption><graphic xlink:href="pone.0006707.g004"/></fig></sec><sec id="s2d"><title>Histological phenotype</title><p>Wt, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e040.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e041.jpg" mimetype="image"/></inline-formula>, and <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice were sacrificed at 100, 200, and 420 days of age, and brains as well as spinal cords were analyzed histologically. By the age of 200 days these mice displayed no pathological alterations with the exception of some Purkinje cells loss in <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (data not shown). When brains of 60 week-old wt (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3B, F, J</xref>), <italic>Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e042.jpg" mimetype="image"/></inline-formula> (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3C, G, K</xref>), <italic>Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e043.jpg" mimetype="image"/></inline-formula> (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3D, H, L</xref>) and <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3E, I, M</xref>) were compared, GFAP immunostains (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3B&#x02013;I</xref>) showed moderate activation of astrocytes within the molecular layer of the cerebellum in PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e044.jpg" mimetype="image"/></inline-formula> mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3D</xref>). No such pathological changes were seen in PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e045.jpg" mimetype="image"/></inline-formula> (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3C</xref>) and wt mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3B</xref>).</p><p>White matter pathology characterized by vacuolation and astrogliosis was seen in the cerebellum (arrows <xref ref-type="fig" rid="pone-0006707-g003">Fig. 3E</xref>) and in the corpus callosum of <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3I</xref>). None of these changes were observed in wt, <italic>Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e046.jpg" mimetype="image"/></inline-formula> and <italic>Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e047.jpg" mimetype="image"/></inline-formula> mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3F&#x02013;H</xref>). Transverse semithin sections of spinal cords (mid-thoracic level, <xref ref-type="fig" rid="pone-0006707-g003">Fig. 3J&#x02013;M</xref>) and of sciatic nerves (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3O&#x02013;R</xref>) revealed coarse vacuolar degeneration (white arrowheads) in myelinated fiber tracts in <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice and axonal loss (white arrows, <xref ref-type="fig" rid="pone-0006707-g003">Fig. 3M, R</xref>). No such changes were observed in wt, <italic>Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e048.jpg" mimetype="image"/></inline-formula> and <italic>Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e049.jpg" mimetype="image"/></inline-formula> mice (<xref ref-type="fig" rid="pone-0006707-g003">Fig. 3J&#x02013;L, O&#x02013;Q</xref>).</p><p>Wt, <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e050.jpg" mimetype="image"/></inline-formula>, <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e051.jpg" mimetype="image"/></inline-formula>, and <italic>Prnp</italic><sup>o/o</sup> mice were sacrificed at 23 days and 60 weeks of age, and brains as well as sciatic nerves were analyzed histologically (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4</xref>). <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e052.jpg" mimetype="image"/></inline-formula> mice of 23 days of age (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4C, G</xref>) displayed no pathological alterations compared to <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e053.jpg" mimetype="image"/></inline-formula> mice which showed strong cerebellar white-matter astrogliosis (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4D</xref>). Transverse semithin sections of the sciatic nerve revealed peripheral neuropathy in <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e054.jpg" mimetype="image"/></inline-formula> with axonal loss white arrows and myelin degeneration white arrowheads (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4H</xref>) but not in wt (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4F</xref>), PrP<sup>o/o</sup> (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4I</xref>) or <italic>Tg40</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e055.jpg" mimetype="image"/></inline-formula> (<xref ref-type="fig" rid="pone-0006707-g004">Fig. 4G</xref>) at 23 days of age. No PrP<sub>&#x00394;CDs</sub> toxicity was observed also at later time points (data not shown).</p></sec><sec id="s2e"><title>Functional rescue of truncated PrP variants</title><p>PrP_Dpl and CD_Dpl did not elicit any clinical or histopathological syndrome in <italic>Prnp</italic><sup>o/o</sup> mice. This may indicate that PrP_Dpl and CD_Dpl have lost all functional characteristics of PrP-like proteins. We assessed this possibility by intercrossing <italic>Tg1026</italic> PrP_Dpl and <italic>Tg1071</italic> CD_Dpl transgenic mice with the neurotoxic PrP deletion mutants <italic>Tg1046</italic> PrP<sub>&#x00394;CD</sub> and <italic>TgF35</italic> PrP<sub>&#x00394;F</sub> mice <xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>, whose toxicity can be ameliorated by the coexpression of full length PrP. The resulting <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e056.jpg" mimetype="image"/></inline-formula> developed first signs of disease at 18&#x02013;20 days post birth and reached terminal disease at 25&#x000b1;0.7 days (n&#x0200a;&#x0003d;&#x0200a;22) of age, as described previously. Double transgenic <italic>Tg1046&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e057.jpg" mimetype="image"/></inline-formula> mice survived until 43&#x000b1;3.3 days (n&#x0200a;&#x0003d;&#x0200a;8), whereas <italic>Tg1046&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e058.jpg" mimetype="image"/></inline-formula> littermates survived 25&#x000b1;2.0 days (n&#x0200a;&#x0003d;&#x0200a;11) (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5A</xref> and <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>). Double-transgenic <italic>Tg1046&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e059.jpg" mimetype="image"/></inline-formula> mice survived 36&#x000b1;1.3 days (n&#x0200a;&#x0003d;&#x0200a;6), as opposed to 26&#x000b1;1.7 days (n&#x0200a;&#x0003d;&#x0200a;6) for <italic>Tg1046&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e060.jpg" mimetype="image"/></inline-formula> littermates (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5C</xref> and <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>). A similar trend was also seen in the transgenic line <italic>Tg1025</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e061.jpg" mimetype="image"/></inline-formula> and in intercrosses of the PrP<sub>&#x00394;CD</sub> lines <italic>Tg1047</italic> and <italic>Tg1050</italic> (data not shown), with significant prolongation of survival (ANOVA; <italic>p</italic>&#x0003c;0.001). <italic>TgF35</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e062.jpg" mimetype="image"/></inline-formula> mice developed ataxia and were euthanized at 96&#x000b1;5.3 days of age (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5B, D</xref> and <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>) as described <xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>. Double transgenic <italic>TgF35&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e063.jpg" mimetype="image"/></inline-formula> mice survived 150&#x000b1;12.7 days (n&#x0200a;&#x0003d;&#x0200a;8; <xref ref-type="fig" rid="pone-0006707-g005">Fig. 5B</xref>; <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>), whereas double transgenic <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e064.jpg" mimetype="image"/></inline-formula> mice survived 139&#x000b1;4.13 days (n&#x0200a;&#x0003d;&#x0200a;11; <xref ref-type="fig" rid="pone-0006707-g005">Fig. 5D</xref>; <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>). In both cases survival was significantly longer (ANOVA; <italic>p</italic>&#x0003c;0.001) than for the single transgenic littermates <italic>TgF35&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e065.jpg" mimetype="image"/></inline-formula> and <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e066.jpg" mimetype="image"/></inline-formula>. In both paradigms one <italic>Prnp</italic> allele sufficed to fully suppress the phenotype of the toxic mutant (data not shown).</p><fig id="pone-0006707-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.g005</object-id><label>Figure 5</label><caption><title>Survival of compound transgenic mice.</title><p>Survival of compound transgenic mice derived from intercrosses between the transgenic lines described above. (A&#x02013;D) Survival curves of mice lacking PrP<sup>C</sup> and expressing various transgenes (PrP<sub>&#x00394;F</sub>, PrP<sub>&#x00394;CD</sub>, CD_Dpl, PrP_Dpl) as indicated by the subscripts. Each line summarizes the survival animals with the respective genotype (group size: 6&#x02013;16 as indicated). (E&#x02013;J) Comparison of histopathological phenotypes in terminally sick PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e067.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e068.jpg" mimetype="image"/></inline-formula> mice with their respective age matched compound littermate transgenic mice. All pictures show GFAP-immunostained cerebellar sections at identical magnification. Terminally sick <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e069.jpg" mimetype="image"/></inline-formula> mice showed astrogliosis both in cerebellar cortex and white matter (E). Milder changes were present in <italic>Tg1046&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e070.jpg" mimetype="image"/></inline-formula> (F) and <italic>Tg1046&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e071.jpg" mimetype="image"/></inline-formula> mice (G). Subtotal granule cell loss associated with severe astrogliosis was seen in the cerebellum of <italic>TgF35</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e072.jpg" mimetype="image"/></inline-formula> mice (H). However, granule cell loss and astrogliosis was less severe in <italic>TgF35&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e073.jpg" mimetype="image"/></inline-formula> mice (I) and almost absent from <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e074.jpg" mimetype="image"/></inline-formula> mice (J). Scale bar&#x0200a;&#x0003d;&#x0200a;5 &#x000b5;m. (K&#x02013;N) Brain expression of PrP<sup>C</sup> and transgenic PrP deletion mutant as well as PrP/Dpl fusion proteins. Specific bands are indicated with arrowheads (K) The expression of CD_Dpl was higher than that of PrP<sub>&#x00394;CD</sub> and PrP<sup>C</sup>. Lanes 1&#x02013;3 represent a serial dilution of a <italic>Tg1046&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e075.jpg" mimetype="image"/></inline-formula> mouse compared to a PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e076.jpg" mimetype="image"/></inline-formula> mouse (lanes 4&#x02013;6). (L) PrP_Dpl expression is similar to that of PrP<sub>&#x00394;CD</sub> and significantly lower than that of PrP<sup>C</sup>. Lanes 1&#x02013;3 represent serial dilutions of <italic>Tg1046&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e077.jpg" mimetype="image"/></inline-formula> mice. The asterisk indicates a carboxy terminal fragment formed from wild-type PrP<sup>C</sup>. (M) Indirect comparison indicates similar PrP<sub>&#x00394;F</sub> and CD_Dpl levels in <italic>TgF35&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e078.jpg" mimetype="image"/></inline-formula> mice which were higher than those of PrP<sup>C</sup>. Lanes 1&#x02013;4 depict a serial dilution of a <italic>TgF35&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e079.jpg" mimetype="image"/></inline-formula> mouse. (N) PrP_Dpl was less abundant than PrP<sub>&#x00394;F</sub> in <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e080.jpg" mimetype="image"/></inline-formula> and <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e081.jpg" mimetype="image"/></inline-formula> mice. Lanes 1&#x02013;3 depict a serial dilution of a <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e082.jpg" mimetype="image"/></inline-formula> mouse compared to a <italic>TgF35&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e083.jpg" mimetype="image"/></inline-formula> mouse (lanes 4&#x02013;6). All brain homogenates were treated with PNGase F, and replica western blots were decorated with antibodies POM1, POM3, and POM11 as indicated below each blot.</p></caption><graphic xlink:href="pone.0006707.g005"/></fig><table-wrap id="pone-0006707-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006707.t002</object-id><label>Table 2</label><caption><title>Survival of compound transgenic mice.</title></caption><alternatives><graphic id="pone-0006707-t002-2" xlink:href="pone.0006707.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Crosses</td><td align="left" rowspan="1" colspan="1">Number of animals</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Average survival &#x0005b;days&#x0005d;</td><td align="left" rowspan="1" colspan="1">Standard deviation of mean &#x0005b;days&#x0005d;</td><td align="left" rowspan="1" colspan="1">Significance</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Tg1046</italic></td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e084.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">25.2</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tg1046&#x000d7;Tg1071</italic></td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e085.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">42.9</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a; p&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tg1046&#x000d7;Tg1026</italic></td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e086.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">36.3</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a; p&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TgF35</italic></td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e087.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">95.6</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TgF35&#x000d7;Tg1071</italic></td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e088.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">150.1</td><td align="left" rowspan="1" colspan="1">12.7</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a; p&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TgF35&#x000d7;Tg1026</italic></td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e089.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">139.1</td><td align="left" rowspan="1" colspan="1">4.1</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a; p&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tg1046</italic></td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e090.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">27.3</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tg1046&#x000d7;Tg42</italic></td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e091.jpg" mimetype="image"/></inline-formula></td><td align="left" rowspan="1" colspan="1">24.8</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">Ns p&#x0003e;0.05</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><p>Mice of various genotypes were housed and monitored according to a 4-degree clinical score system. Terminally sick animals were euthanized. Mean survivals of single-transgenic littermates were compared to double transgenic mice and statistical significance of difference was tested by ANOVA.</p></fn></table-wrap-foot></table-wrap><p>Histological analysis of terminally sick <italic>Tg1046</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e092.jpg" mimetype="image"/></inline-formula> mouse brains revealed astrogliosis both in the corpus callosum (not shown) and in the cerebellar white matter (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5E</xref>) while <italic>TgF35</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e093.jpg" mimetype="image"/></inline-formula> mice displayed additional severe cerebellar granule cell (CGC) loss (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5H</xref>). Milder white-matter changes and much less severe CGC loss were observed in compound <italic>Tg1046&#x000d7;Tg1071</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e094.jpg" mimetype="image"/></inline-formula> and <italic>Tg1046&#x000d7;Tg1026</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e095.jpg" mimetype="image"/></inline-formula> littermates euthanized at the same age (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5F&#x02013;G and 5I&#x02013;J</xref>). Western blot analysis of brain homogenates indicated that expression levels of the various transgenic proteins were unchanged in the compound transgenic mice independently of the respective combination. The steady-state levels of CD_Dpl exceeded those of PrP<sub>&#x00394;CD</sub> PrP<sub>&#x00394;F</sub> and PrP<sup>wt</sup> (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5K, M</xref>), whereas those of PrP_Dpl and PrP<sub>&#x00394;CD</sub> were similar and much lower than those of PrP<sub>&#x00394;F</sub> (<xref ref-type="fig" rid="pone-0006707-g005">Fig. 5L, N</xref>). Although expression of CD_Dpl was higher than that of PrP_Dpl, and compound PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e096.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e097.jpg" mimetype="image"/></inline-formula> mice displayed longer survival than PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e098.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e099.jpg" mimetype="image"/></inline-formula> mice, CD_Dpl seemed to be less effective than PrP_Dpl to suppress cerebellar granule cell loss. This finding may point to a specific function of the amino proximal regions in suppressing neurodegeneration.</p><p>In order to address the functionality of PrP<sub>&#x00394;CDs</sub>, we intercrossed <italic>Tg42</italic> PrP<sub>&#x00394;CDs</sub> and <italic>Tg1046</italic> PrP<sub>&#x00394;CD</sub> mice and monitored the offspring for clinical signs of disease. <italic>Tg1046</italic>&#x000d7;<italic>Tg42</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e100.jpg" mimetype="image"/></inline-formula> were found to develop first signs of disease at 18&#x02013;20 days post birth, and reached terminal disease at 25&#x000b1;0.71 days of age (n&#x0200a;&#x0003d;&#x0200a;22; <xref ref-type="fig" rid="pone-0006707-g004">Fig. 4A</xref> and <xref ref-type="table" rid="pone-0006707-t002">Table 2</xref>). Double transgenic <italic>Tg1046&#x000d7;Tg42</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e101.jpg" mimetype="image"/></inline-formula> mice survived for 25&#x000b1;1.9 days. Hence there was no significant difference in survival. All single or double transgenic mice coexpressing PrP<sup>C</sup>: <italic>Tg1046&#x000d7;Tg42</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e102.jpg" mimetype="image"/></inline-formula>, and <italic>Tg1046&#x000d7;Tg42</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e103.jpg" mimetype="image"/></inline-formula> survived to old age without any signs of clinical disease, indicating that PrP<sub>&#x00394;CDs</sub> does not diminish the potential of PrP<sup>C</sup> to ameliorate PrP<sub>&#x00394;CD</sub> induced toxicity. In contrast, PrP<sub>&#x00394;F</sub> and PrP<sub>&#x00394;CD</sub> were previously shown to compete for the rescue effect of PrP<sup>C</sup> in double transgenic mice <italic>Tg1046&#x000d7;TgF35</italic> PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e104.jpg" mimetype="image"/></inline-formula><xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. We therefore conclude that removal of the lipid anchor from PrP<sub>&#x00394;CD</sub> completely abolishes its neurotoxic properties.</p></sec></sec><sec id="s3"><title>Discussion</title><p>The results presented here confirm and extend a recent report that fusion of the complete amino-terminus of PrP detoxifies Dpl. Tg(PrPN-Dpl) mice expressing a fusion protein consisting of amino acids 1&#x02013;124 of PrP and amino acids 58&#x02013;179 of Dpl failed to show Dpl typical neurological disorder and were able to prolong the onset of ataxia in mice with exogenous Dpl expression <xref ref-type="bibr" rid="pone.0006707-Yoshikawa1">&#x0005b;24&#x0005d;</xref>. By generating chimeric proteins that contain either the entire amino-terminus of PrP linked to the carboxy-terminus of Dpl (PrP_Dpl) or the central domain of PrP alone (CD_Dpl), we found specific domains within the amino-terminus of PrP that are involved in the detoxification of Dpl in two distinct brain regions and cell types.</p><p>While PrP_Dpl showed no signs of cerebellar granule cell degeneration for at least 60 weeks, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e105.jpg" mimetype="image"/></inline-formula> mice displayed mild astrogliosis within the CGC layer. This may point to some residual neurotoxicity of CD_Dpl. In contrast, white matter degeneration was observed in Dpl-expressing Ngsk mice yet was not seen in mice expressing either of the two transgenes, PrP_Dpl and CD_Dpl. Since leukoencephalopathy is the major life-shortening pathology associated with expression of truncated PrP and Dpl <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Radovanovic1">&#x0005b;33&#x0005d;</xref>, both addition of the whole amino-terminus, or addition of the central domain alone resulted in a normal life expectancy in transgenic mice.</p><p>In addition to detoxifying Dpl, chimeric fusion proteins were able to partially antagonize the toxic effects of the PrP deletion mutants PrP<sub>&#x00394;F</sub> and PrP<sub>&#x00394;CD</sub>. While PrP_Dpl was able to antagonize cerebellar granule cell loss in PrP<sub>&#x00394;F</sub> mice, CD_Dpl was not. Cerebellar white matter gliosis was milder in both PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e106.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e107.jpg" mimetype="image"/></inline-formula> mice. This lends further support to the conclusion that distinct domains within PrP exert neurotrophic functions in a variety of brain regions and cell types.</p><p>We have excluded that differences in expression level were responsible for the observed effects: Western blotting with antibody POM3 <xref ref-type="bibr" rid="pone.0006707-Polymenidou1">&#x0005b;31&#x0005d;</xref>, which recognizes a domain common to both transgenes, showed a higher expression for CD_Dpl than for PrP_Dpl. All transgenic constructs were expressed using the same backbone, thereby reducing the likelihood of differential expression in distinct cell types. Thus the cell-specific effects of the different transgenes appear to be related to their structural features rather than to the levels or tissue-specific patterns of their expression.</p><p>Despite sequence homologies of &#x0003c;20&#x00025;, the carboxy terminal domains of Dpl and PrP have very similar folding patterns of the respective carboxy proximal regions, whereas their amino proximal portions are much less structured <xref ref-type="bibr" rid="pone.0006707-Luhrs1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Zahn1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Riek1">&#x0005b;35&#x0005d;</xref>. Hence the selective permutations of the less structured domains of the two proteins performed here are not very likely to alter the overall global fold of the resulting fusion proteins. We found that both PrP_Dpl and CD_Dpl underwent correct intracellular sorting and posttranslational processing (<xref ref-type="fig" rid="pone-0006707-g002">Fig. 2A, C</xref>). Furthermore, in none of the transgenic mice (including the lines expressing the highest levels of transgene) did we detect any spontaneous formation of PK-resistant transgenic protein or PrP aggregates by Western blotting and histology (data not shown).</p><p>Further evidence for specific differences in the function of PrP<sup>C</sup> comes from the previous studies on transgenic mice expressing PrP<sup>C</sup> in a cell-type specific manner. While cerebellar granule cell loss in PrP<sub>&#x00394;F</sub> mice was reversed by neuronal expression of PrP, white matter degeneration was rescued by myelin-specific expression of PrP <xref ref-type="bibr" rid="pone.0006707-Radovanovic2">&#x0005b;36&#x0005d;</xref>.</p><p>Cell-specific requirements for distinct PrP domains might explain the discrepancies regarding the domains reported to be involved in cytotrophic functions. Several studies suggest that the octapeptide repeat region is crucially linked to the neuroprotective functions of PrP<sup>C</sup><xref ref-type="bibr" rid="pone.0006707-Chacon1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Drisaldi1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Mitteregger1">&#x0005b;39&#x0005d;</xref>. On the other hand, a feature common to all the toxic PrP deletion mutants is the lack of the central domain (encompassing at least residues 105&#x02013;125) within PrP<sup>C</sup>. This in turn points to a role of the central domain of PrP<sup>C</sup>.</p><p>The results presented here may help clarifying this controversy. The central domain (aa 94&#x02013;134) appears to be crucial for myelin maintenance, while other domains within the amino terminus (aa 23&#x02013;94) may be required for neuroprotection. Residues 23&#x02013;94 consists of the amino-terminal charged cluster (aa 23&#x02013;28) involved in endocytosis and of the octapeptide repeat region associated with neuroprotection via anti-oxidative function and copper binding (aa 50&#x02013;90) <xref ref-type="bibr" rid="pone.0006707-Chacon1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Mitteregger1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-VarelaNallar1">&#x0005b;40&#x0005d;</xref>. It was initially reported that amino acids 23&#x02013;88 are needed to fully suppress neurotoxicity on Purkinje cells <xref ref-type="bibr" rid="pone.0006707-Atarashi1">&#x0005b;41&#x0005d;</xref>, yet it was later shown that the octapeptide repeats are dispensable for this function. This suggests that the charge cluster may be more relevevant for the neuroprotection of Purkinje cells <xref ref-type="bibr" rid="pone.0006707-Yoshikawa1">&#x0005b;24&#x0005d;</xref> that for other cell types. It is less likely that toxic domains within the amino-terminus of Dpl in CD_Dpl may be responsible for the observed residual neurotoxicity, since earlier studies showed that the proximate cause of cerebellar granule cell degeneration is not the amino terminus of Dpl, but rather its carboxy terminus <xref ref-type="bibr" rid="pone.0006707-Drisaldi2">&#x0005b;42&#x0005d;</xref>.</p><p>PrP<sup>C</sup> was reported to inhibit the NR2D subunits of the NMDA receptor complex, and <italic>Prnp<sup>o/o</sup></italic> hippocampal neurons display increased neuronal excitability and enhanced glutamate excitotoxicity <xref ref-type="bibr" rid="pone.0006707-Khosravani1">&#x0005b;43&#x0005d;</xref>. It will be interesting to study whether chimeric PrP/Dpl proteins exert PrP<sup>C</sup> like functional regulation of the NMDA receptor and whether central domain, octapeptide repeat region or amino-terminal charged cluster are involved in this function.</p><p>It was suggested that homodimerization of PrP<sup>C</sup> mediates the transduction of extracellular signals <xref ref-type="bibr" rid="pone.0006707-Mattei1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-MouilletRichard2">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Solforosi1">&#x0005b;46&#x0005d;</xref>. The toxicity of truncated PrP and Dpl is counteracted by overexpression of full-length PrP<sup>C</sup><xref ref-type="bibr" rid="pone.0006707-Shmerling1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Yamaguchi1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Moore2">&#x0005b;19&#x0005d;</xref> and exacerbated by removal of the endogenous <italic>Prnp</italic> gene, suggesting that PrP<sup>C</sup> and its variants compete for a common interacting molecule. The PrP/Dpl fusion proteins appear to partake in this competition as well, as both CD_Dpl and PrP_Dpl prolonged survival of PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e108.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e109.jpg" mimetype="image"/></inline-formula> mice. Perhaps the CD region is responsible for stringent protein-protein interactions, whereas the structured carboxy termini of PrP and Dpl allow for more relaxed interactions and are therefore interchangeable. Such interactions might also include the formation of functionally relevant homodimers or homooligomers <xref ref-type="bibr" rid="pone.0006707-Behrens2">&#x0005b;47&#x0005d;</xref>. The residues 113&#x02013;128 of PrP mediate interaction of PrP with stress inducible protein 1 (STI) <xref ref-type="bibr" rid="pone.0006707-Zanata1">&#x0005b;48&#x0005d;</xref> and heparan sulfate <xref ref-type="bibr" rid="pone.0006707-Warner1">&#x0005b;49&#x0005d;</xref>. The incompleteness of the rescue in all tested paradigms of PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e110.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e111.jpg" mimetype="image"/></inline-formula>, PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e112.jpg" mimetype="image"/></inline-formula> and PrP<inline-formula><inline-graphic xlink:href="pone.0006707.e113.jpg" mimetype="image"/></inline-formula> mice may relate to insufficient amounts of the respective fusion proteins, or possibly to reduced affinity for their binding partners.</p><p>In addition to the findings described above, we extended our analysis of functional domains within PrP to those determining the localization of the protein. Mice expressing anchorless PrP accumulate high titers of prions and protease-resistant PrP when challenged with scrapie <xref ref-type="bibr" rid="pone.0006707-Chesebro1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006707-Trifilo1">&#x0005b;50&#x0005d;</xref>, yet develop only subtle pathologies <xref ref-type="bibr" rid="pone.0006707-Trifilo2">&#x0005b;51&#x0005d;</xref>. Here, anchorless PrP<sub>&#x00394;CDs</sub> was expressed to high levels in transgenic mice, and was very efficiently secreted into the extracellular space of brain and in serum as a mature, fully glycosylated soluble form <xref ref-type="bibr" rid="pone.0006707-Aguzzi2">&#x0005b;52&#x0005d;</xref>. Although the deletion within PrP<sub>&#x00394;CDs</sub> was identical to that of the neurotoxic membrane anchored PrP<sub>&#x00394;CD</sub>, it did not induce any pathology in transgenic mice, irrespectively of the presence or absence of full-length PrP<sup>C</sup>. Since the total concentration of PrP<sub>&#x00394;CDs</sub> in brain homogenates was as high as that of PrP<sub>&#x00394;CD</sub>, and even higher than that of PrP<sub>&#x00394;CD</sub> in the serum, lack of toxicity was unrelated to its expression level. Also, PrP<sub>&#x00394;CDs</sub> failed to influence the survival of PrP<sub>&#x00394;CD</sub> mice coexpressing PrP<sup>C</sup>, confirming that it exerts neither beneficial nor detrimental effects on the central nervous system.</p><p>PrP<sub>&#x00394;CDs</sub> did not localize to detergent-resistant membrane (DRM) fractions, even when wild-type PrP<sup>C</sup> was coexpressed. This observation suggests that the genetic interaction between PrP<sup>C</sup> and its neurotoxic variants may physically necessitate membrane anchoring of all relevant partners. In contrast, soluble-dimeric prion protein (PrP-Fc<sub>2</sub>) was found to translocate to the DRM compartment and to associate with PrP<sup>Sc</sup> upon prion infection of mice coexpressing PrP<sup>C</sup> and PrP-Fc<sub>2</sub><xref ref-type="bibr" rid="pone.0006707-Trifilo2">&#x0005b;51&#x0005d;</xref>. In this context, it may be of interest to study the localization of PrP<sub>&#x00394;CDs</sub> in prion infected mice.</p><p>In conclusion, the above findings indicate that (1) the amino proximal domain of PrP contains minimal elements that are necessary and sufficient for PrP function, that (2) distinct domains within the amino-terminus of PrP exert site- and/or cell-specific functions, and that (3) GPI membrane anchoring is mandatory for exerting said function. The understanding of the physiological and pathophysiological functions of the prion protein will benefit from functional analyses of the proteinaceous <xref ref-type="bibr" rid="pone.0006707-Zanata1">&#x0005b;48&#x0005d;</xref> and non proteinaceous <xref ref-type="bibr" rid="pone.0006707-Warner1">&#x0005b;49&#x0005d;</xref> constituents interacting with PrP and its variants. Finally, it will be of particular interest to explore whether the phenomena studied here share functional and molecular aspects with the neurotoxicity observed in prion diseases <xref ref-type="bibr" rid="pone.0006707-Aguzzi3">&#x0005b;53&#x0005d;</xref>.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Ethics Statement</title><p>All mice were maintained under specific pathogen-free (SPF) conditions. Housing and experimental protocols were in accordance with the Swiss Animal Protection Law and in compliance with the regulations of the Veterinaeramt, Kanton Zurich.</p></sec><sec id="s4b"><title>Construction of the transgenes</title><p>The coding region of murine <italic>Prnp</italic> and Prnd gene were analyzed using DNAMAN software (Lynnon BioSoft, Canada), and hydrophobicity plots were generated using a window of 9 amino acid residues. The regions identified in these plots were used to define the CC, CD and HC domains. The chimeric fusion proteins of PrP and Dpl were designed such that their hydrophobicity characteristics would mimic that of wild-type PrP. Based on pPrPHG <xref ref-type="bibr" rid="pone.0006707-Fischer1">&#x0005b;25&#x0005d;</xref>, a <italic>Pme</italic>I/<italic>Nhe</italic>I fragment was subcloned in the pMECA <xref ref-type="bibr" rid="pone.0006707-Griffiths1">&#x0005b;54&#x0005d;</xref> backbone. To create the CD_Dpl cDNA, mouse genomic cDNA was used as template to obtain two PCR fragments with primer sets JP1 (<named-content content-type="gene">5&#x02032;-ATA ATA ATG CAT ACC ACC ATG AAG AAC CGG CTG GGT AC</named-content>)/JP2 (<named-content content-type="gene">5&#x02032;-TAC TGC CCC AGC TGC CGC AGC CCC TGC CAC ATG CTT GAG GTT GGT TTT TGG TTT GCT GGG CTT GTT CCA CTG ATT ATG GGT ACC CCC TCC CCG GCC TTG CTT GAT GAA GG</named-content>) and JP3 (<named-content content-type="gene">5&#x02032;-CCT CAA GCA TGT GGC AGG GGC TGC GGC AGC TGG GGC AGT AGT GGG GGG CCT TGG TGG CTA CAT GCT GGG GAG CGC CGT GAG CAG GCC CAT GAA GCT GGA CAT CGACTT TGG</named-content> )/JP4 (<named-content content-type="gene">5&#x02032;-ATA ATA ATG CAT TTA CTT CAC AAT GAA CCA AAC</named-content>). The two initial products were fused in a third PCR with the flanking primers JP1 and JP4. This product was digested with <italic>Nsi</italic>I and ligated to the <italic>Nsi</italic>I sites of the pMECA vector containing the pPrPHG subcloned <italic>Pme</italic>I/<italic>Nhe</italic>I sequence into which a second <italic>Nsi</italic>I site had been engineered. After confirming insertion with the correct orientation, the insert was cloned back into the pPrPHG backbone using the <italic>Pme</italic>I/<italic>Nhe</italic>I sites.</p><p>PrP_Dpl was created based on the plasmid pPrPHG <xref ref-type="bibr" rid="pone.0006707-Fischer1">&#x0005b;25&#x0005d;</xref>. A fragment (480 bp) was amplified using the primers pE2&#x0002a; (<named-content content-type="gene">5&#x02032;-CAA CCG AGC TGA AGC ATT CTG CCT</named-content>)/X2 (<named-content content-type="gene">5&#x02032;-CCT GCT CAC GGC GCT CCC CAG CAT G</named-content>) containing sequence information from Exon3 to codon 132/133 of the murine PrP. In a second PCR using genomic DNA as template and primers X3 (<named-content content-type="gene">5&#x02032;-GGG AGC GCC GAC ATC GAC</named-content>)/X4 (<named-content content-type="gene">5&#x02032;-AAA GAA TTC CAC AAT TCT TAC TTC ACA ATG</named-content>) a fragment (360 bp) containing codon 68 until polyadenylation site of Dpl was amplified. After purification both fragments were cut with <italic>Hae</italic>II mixed and directly ligated into the pCR-Blunt II-Topo vector. The transgene was then excised with <italic>Age</italic>I/<italic>Eco</italic>RI and, after blunting the 3&#x02032; <italic>Eco</italic>RI sites, ligated into the original <italic>Age</italic>I/BbrPI site of pPrPHG. The presence of the new insert was confirmed by restriction analysis using <italic>Sma</italic>I.</p><p>PrP<sub>&#x00394;CDs</sub> was generated using the pMECA <italic>Pme</italic>I/<italic>Nhe</italic>I subclone pPrPHG previously described <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. The oligonucleotide primers dCDSol5&#x02032; (<named-content content-type="gene">5&#x02032;-CCT ATT ACG ACG GGA GAA GAT CCT GAT GAA CCG TGC TTT TCT CCT CC-3&#x02032;</named-content>) dCDSol3&#x02032; (<named-content content-type="gene">5&#x02032;- GGA GGA GAA AAG CAC GGT TCA TCA GGA TCT TCT CCC GTC GTA ATA GG-3&#x02032;</named-content>), each complementary to opposite strands of the vector, were extended during temperature cycling by <italic>PfuTurbo</italic>&#x000ae; DNA polymerase. On incorporation of the oligonucleotide primers, a mutated plasmid containing staggered nicks was generated. After temperature cycling and treatment with <italic>Dpn</italic>I to digest the parental DNA template and select for the desired DNA construct, the nicked vector DNA incorporating the mutations was transformed into E. coli. Clones were picked and sequenced. Finally the <italic>Pme</italic>I/<italic>Nhe</italic>I fragment containing the desired point mutation was religated into the pPrPHG vector as described before <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>.</p></sec><sec id="s4c"><title>Generation, Identification, and Maintenance of Transgenic Mice</title><p>The pPrPHG plasmids containing the PrP or Dpl coding sequences were propagated in E. coli XL1 blue, the minigene excised with <italic>Not</italic>I and <italic>Sal</italic>I, and processed as described <xref ref-type="bibr" rid="pone.0006707-Fischer1">&#x0005b;25&#x0005d;</xref>. Pronuclear injections into fertilized oocytes were carried out as described <xref ref-type="bibr" rid="pone.0006707-Rulicke1">&#x0005b;55&#x0005d;</xref>. Transgenes on a <italic>Prnp</italic><sup>o/o</sup> background were identified by PCR using the exon 2 primer pE2&#x0002a; (<named-content content-type="gene">5&#x02032;-CAA CCG AGC TGA AGC ATT CTG CCT</named-content>) and the exon 3 primer Ubl floxed Dpl (<named-content content-type="gene">5&#x02032;-CTC GCT GGT GGA GCT TGC TAT C</named-content>) resulting in a PCR product of 618 bp for CD_Dpl and 670 bp for PrP_Dpl or pE2&#x0002a; and exon 3 primer Mut217 (<named-content content-type="gene">5&#x02032;-CCT GGG ACT CCT TCT GGT ACC GGG TGA CGC</named-content>) resulting in a PCR product of 619 bp. PCR analysis in order to verify the outbreeding of the <italic>Prnp</italic><sup>&#x0002b;</sup> allele was carried out using primers P10 (<italic>Prnp</italic> exon 3, <named-content content-type="gene">5&#x02032;-GTA CCC ATA ATC AGT GGA ACA AGC CCA GC</named-content>), 3&#x02032;NC (non-coding region at 3&#x02032; of exon 3, <named-content content-type="gene">5&#x02032;-CCC TCC CCC AGC CTA GAC CAC GA</named-content>), and P3 (neoR gene, <named-content content-type="gene">5&#x02032;-ATT CGC AGC GCA TCG CCT TCT ATC GCC</named-content>); P10 and 3&#x02032;NC gave an 560 bp signal for the <italic>Prnp</italic><sup>&#x0002b;</sup> allele, and P3 and 3&#x02032;NC gave a 362 bp product for the <italic>Prnp</italic><sup>0</sup> allele. Alternatively, to test for the presence or absence of the <italic>Prnp</italic><sup>&#x0002b;</sup> allele an additional PCR was performed using primers P2 (<italic>Prnp</italic> int 2, <named-content content-type="gene">5&#x02032;-ATA CTG GGC ACT GAT ACC TTG TTC CTC AT</named-content>) and P10rev (reverse complementary of P10 <named-content content-type="gene">5&#x02032;-GCT GGG CTT GTT CCA CTG ATT ATG GGT AC</named-content>) giving a product of 352 bp for the <italic>Prnp</italic><sup>&#x0002b;</sup> allele. In order to distinguish between transgenic mice expressing PrP<sub>&#x00394;CD</sub> and PrP<sub>&#x00394;CDs</sub>, two separate PCR reactions were performed using primers pE2&#x0002a; and pdCDrev (<named-content content-type="gene">5&#x02032;-GGA GGA GAA AAG CAC GGT GCT GCT</named-content>) yielding a diagnostic amplicon of 666 bp, or using pE2&#x0002a; and pdCDsrev (<named-content content-type="gene">5&#x02032;-GGA GGA GAA AAG CAC GGT TCA TCA</named-content>) yielding a diagnostic amplicon of 666 bp.</p></sec><sec id="s4d"><title>Q-PCR to determine genomic copy numbers</title><p>Total genomic DNA was prepared from mouse tails after PK digestion and purified according to standard procedures. Copy numbers were assessed by Taqman PCR using 2 ng of total genomic DNA and primer pairs CD Sonde5&#x02032; (<named-content content-type="gene">5&#x02032;-GGA GGG GGT ACC CAT AAT</named-content>) and CD Sonde3&#x02032; (<named-content content-type="gene">5&#x02032;- GCG CTC CCC AGC ATG TAG</named-content>) on C57Bl6, <italic>Tga20</italic>, <italic>Prnp</italic><sup>o/o</sup>, <italic>Tg1025</italic>, Tg1026 and <italic>Tg1071</italic> mice. For determination of copy numbers of <italic>Tg40</italic>, <italic>Tg42</italic> primer pairs p60 (<named-content content-type="gene">5&#x02032;-CGC TAC CCT AAC CAA GTG T</named-content>) and p61 (<named-content content-type="gene">5&#x02032;-GAT CTT CTC CCG TCG TAA T</named-content>) were used. To standardize Taqman PCR on GAPDH using primers GAPDH up (<named-content content-type="gene">5&#x02032;-CCA CCC CAG CAA GGA GAC T</named-content>) and GAPDH down (<named-content content-type="gene">5&#x02032;-GAA ATT GTG AGG GAG ATG CT</named-content>) was done in parallel.</p></sec><sec id="s4e"><title>mRNA analysis</title><p>Total brain RNA was isolated in Trizol (Life Technologies), purified and DNase treated according to the manufacturer's manual (Roche). After reverse transcription (Geneamp; Roche) cDNA was used for Taqman PCR using primer pairs Dpl Taq5&#x02032; (<named-content content-type="gene">5&#x02032;-CTA CGC GGC TAA CTA TTG</named-content>)/Dpl Taq3&#x02032; (<named-content content-type="gene">5&#x02032;-CGC CGG TTG GTC CAC</named-content>) and PrP Taq5&#x02032; (<named-content content-type="gene">5&#x02032;-CAG TGG AAC AAG CCC AGC</named-content>)/PrP Taq3&#x02032; (<named-content content-type="gene">5&#x02032;-CCC CAG CAT GTA GCC ACC</named-content>). To standardize expression levels GAPDH using primers GAPDH up (<named-content content-type="gene">5&#x02032;-CCA CCC CAG CAA GGA GAC T</named-content>) and GAPDH down<named-content content-type="gene"> (5&#x02032;-GAA ATT GTG AGG GAG ATG CT</named-content>) and 18S rRNA using primers 18S fw (<named-content content-type="gene">5&#x02032;-GTA ACC CGT TGA ACC CCA TT</named-content>) and 18S rc (<named-content content-type="gene">5&#x02032;-CCA TCC AAT CGG TAG TAG CG</named-content>) were used. Taqman PCR using SYBR-green (Roche) and determination of &#x00394;&#x00394;CT-values were done on a Applied Biosystems 7900 device. As control for possible DNA contamination, DNase-treated RNA from wt and tg mice that had not been reversely transcribed was used.</p></sec><sec id="s4f"><title>Western blot analysis</title><p>Brain hemispheres were homogenized in 7 vol PBS, 0.5&#x00025; Nonidet P-40, and 0.5&#x00025; deoxycholate and the solution was centrifuged 5 min in an Eppendorf centrifuge. For deglycosylation, up to 50 &#x000b5;g denatured total protein were incubated at 37&#x000b0;C for 4 h with 500 U PNGase F (New England Biolabs) according to the manufacturer's instructions. The protease inhibitors Pefabloc (1 mg/ml), Leupeptin (10 &#x000b5;g/ml), Pepstatin (10 &#x000b5;g/ml), Aprotinin (1 &#x000b5;g/ml) (all from Boehringer, Mannheim), and 0.5 mg/ml EDTA were added. After electrophoresis of protein samples through 12&#x00025; SDS-polyacrylamide gels, samples were transferred to nitrocellulose membranes (Schleicher &#x00026; Schuell) and incubated with mouse monoclonal anti-PrP antibodies POM1, POM3 and POM11 <xref ref-type="bibr" rid="pone.0006707-Polymenidou1">&#x0005b;31&#x0005d;</xref>, followed by incubation with peroxidase-labeled anti-mouse antiserum (1&#x02236;2500; Amersham) and developed with the ECL detection system (Pierce). Antibody incubations were performed in 1&#x00025; Top Block (Juro) in Tris-buffered saline-Tween (TBS-T) for 1 h at room temperature or overnight at 4&#x000b0;C.</p></sec><sec id="s4g"><title>Flotation assays</title><p>Flotation of detergent insoluble complexes was performed as described <xref ref-type="bibr" rid="pone.0006707-Naslavsky1">&#x0005b;56&#x0005d;</xref>. Appropriate brain homogenates were extracted for 2 h on ice in cold lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1&#x00025; Triton X-100; total protein: 1 mg in 1.6 ml. Extracts were mixed with two volumes (3.2 ml) of 60&#x00025; Optiprep&#x000ae; (Nycomed) to reach a final concentration of 40&#x00025;. All lysates were loaded at the bottom of Beckman ultracentrifuge tubes. A 5&#x02013;30&#x00025; Optiprep&#x000ae; step gradient in TNE (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA) was then overlaid onto the lysate (8.4 ml of 30&#x00025; Optiprep&#x000ae; and 3.6 ml of 5&#x00025; Optiprep&#x000ae;). Tubes were centrifuged for 24 h at 4&#x000b0;C in a TLS55 Beckman rotor at 100,000 <italic>g</italic>. Fractions (1 ml) were collected from the top of the tube and processed for immunoblotting and visualization with anti-PrP antibody POM3 <xref ref-type="bibr" rid="pone.0006707-Polymenidou1">&#x0005b;31&#x0005d;</xref>, anti-flotillin 1, and anti-GAPDH antibody (both BD Transduction Laboratories). In order to release GPI anchored proteins from membranes, brain homogenates were treated for 2 h at 37&#x000b0;C with 10 U/ml Phospholipase C (PI-PLC from Sigma) as described <xref ref-type="bibr" rid="pone.0006707-Hornemann1">&#x0005b;57&#x0005d;</xref>.</p></sec><sec id="s4h"><title>ELISA</title><p>PrP ELISA was performed as described in <xref ref-type="bibr" rid="pone.0006707-Polymenidou2">&#x0005b;58&#x0005d;</xref> 96-well plates (Nunc-Immuno Maxisorb; prod. no. 439454) were coated with 50 &#x000b5;L per well of POM1 (2 mg/ml, 1&#x02236;5000 in 0.1 M sodium carbonate buffer pH 9.6 &#x0005b;1.58 g Na<sub>2</sub>CO<sub>3</sub>&#x0002b;2.94 g NaHCO<sub>3</sub> in 500 ml H<sub>2</sub>O&#x0005d;) over night at 4&#x000b0;C. All following incubation steps were made at room temperature. The plates were washed by immersing them 4&#x02013;5 times in PBS with 0.1&#x00025; Tween-20 (PBST). Plates were then incubated with 100 &#x000b5;L per well of blocking buffer (5&#x00025; Top-Block in PBST) for two hours. A 1&#x02236;3 dilution of recombinant murine PrP (rmPrP) (starting from 50 ng/ml) was used for a standard curve. Blood plasma from respective mice was diluted appropriately in sample buffer (1&#x00025; Top-Block in PBST) and incubated for 1 h. Then, plates were washed 4&#x02013;5 times in PBST and incubated with biotin-labeled POM2 (1 mg/ml, 1&#x02236;5000 in sample buffer, 100 &#x000b5;L per well) for 1 h. Plates were washed 4&#x02013;5 times and incubated with avidin-HRP (1 mg/ml, 1&#x02236;1000 in sample buffer, 100 &#x000b5;L per well) for 1 h followed by another round of washing, 4&#x02013;5 times in PBST and 2&#x02013;3 times with PBS alone. Chromogenic substrate (Biosource, prod. no. SB02, 50 &#x000b5;L per well) was applied for up to 10 min. The reaction was stopped with 0.5 M H<sub>2</sub>SO<sub>4</sub> and absorbance was read at 450 nm.</p></sec><sec id="s4i"><title>Clinical scoring and observation</title><p>Mice were examined once weekly for clinical signs as described previously <xref ref-type="bibr" rid="pone.0006707-Baumann1">&#x0005b;10&#x0005d;</xref>. Mice were euthanized when they reached a score of 3.5 or higher. Statistical significance was assessed as indicated.</p></sec><sec id="s4j"><title>Morphological analyses</title><p>Brains, spinal cords and sciatic nerves were removed and fixed in 4&#x00025; formaldehyde in PBS, pH 7.5, paraffin embedded, and cut into 2&#x02013;4 &#x000b5;m sections. Sections were stained with hematoxylin-eosin (H&#x00026;E), Luxol-Nissl (myelin and neurons), and commercial antibodies to GFAP (glial fibrillary acidic protein; activated astrocytes), MBP (myelin basic protein), NF200 (neurofilament 200), IBA1 (microglia) and SAF84 (PrP<sup>Sc</sup> aggregates). For semithin sections and electron microscopy mice were perfused with ice-cold 4&#x00025; PFA/3.9&#x00025; glutaraldehyde. Spinal cord tissues were removed, immersed in the same solutions, and kept in Phosphate buffer at 4&#x000b0;C until processing. Tissues were embedded in Epon, and semithin sections were stained with toluidine blue and paraphenylene diamine. Frozen sections for POM3 and Dpl staining were blocked with M.O.M Mouse IgG Blocking Reagent (Vector Laboratories) stained with anti Dpl GX-2D10-B1 (Dpl) or POM3 (soluble cellular PrP). Detection was achieved using both Goat anti Mouse AP and Donkey anti Goat AP (Jackson) with alkaline phosphatase fast red.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0006707.s001"><label>Figure S1</label><caption><p>Characterization of transgenic mice (A) Gene copy numbers per haploid genome in transgenic lines as determined by genomic Q-PCR. (B) relative mRNA level in brain extracts of transgenes compared to PrP mRNA in C57BL/6 mice (filled black columns and left y-axis) and compared Dpl mRNA in <italic>Prnp</italic><sup>Ngsk/Ngsk</sup> mice (open columns and right y-axis) using either PrP or Dpl specific primer sets for Q-PCR. Each column represents the average of 3 mice.</p><p>(0.55 MB TIF)</p></caption><media xlink:href="pone.0006707.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006707.s002"><label>Figure S2</label><caption><p>Characterization of membrane anchored and PI-PLC treated transgenic proteins. Density gradient DRM preparations of wild-type, PrP GPI anchorless (PrP<sub>s</sub>), PrP<sub>&#x00394;CD</sub> and PrP<sub>&#x00394;CDs</sub> transgenic brains analyzed after PI-PLC treatment and deglycosylation with PNGase F with monoclonal antibody POM1. After PI-PLC treatment PrP and PrP<sub>&#x00394;CD</sub> had similarly buoyancy like PrPs and PrP<sub>&#x00394;CDs</sub> whereas flotillin a non GPI-anchored DRM associated protein still was found in fractions with higher buoyancy indicating the intactness of the DRMs.</p><p>(0.84 MB TIF)</p></caption><media xlink:href="pone.0006707.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Petra Schwarz, Rita Moos, Marianne K&#x000f6;nig, Andrea Schifferli, Cinzia Tiberi, Li-Chun Infanger, and Dimitri Gourionov for technical assistance. We also thank Drs. Bruce Chesebro and Michael Oldstone for kindly providing PrP<sub>s</sub> mice.</p></ack><ref-list><title>References</title><ref id="pone.0006707-Prusiner1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year>1982</year><article-title>Novel proteinaceous infectious particles cause scrapie.</article-title><source>Science</source><volume>216</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">6801762</pub-id></mixed-citation></ref><ref id="pone.0006707-Oesch1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oesch</surname><given-names>B</given-names></name><name><surname>Westaway</surname><given-names>D</given-names></name><name><surname>Walchli</surname><given-names>M</given-names></name><name><surname>McKinley</surname><given-names>MP</given-names></name><name><surname>Kent</surname><given-names>SB</given-names></name><etal/></person-group><year>1985</year><article-title>A cellular gene encodes scrapie PrP 27&#x02013;30 protein.</article-title><source>Cell</source><volume>40</volume><fpage>735</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">2859120</pub-id></mixed-citation></ref><ref id="pone.0006707-Bendheim1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendheim</surname><given-names>PE</given-names></name><name><surname>Brown</surname><given-names>HR</given-names></name><name><surname>Rudelli</surname><given-names>RD</given-names></name><name><surname>Scala</surname><given-names>LJ</given-names></name><name><surname>Goller</surname><given-names>NL</given-names></name><etal/></person-group><year>1992</year><article-title>Nearly ubiquitous tissue distribution of the scrapie agent precursor protein.</article-title><source>Neurology</source><volume>42</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">1346470</pub-id></mixed-citation></ref><ref id="pone.0006707-Beler1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;eler</surname><given-names>HR</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Sailer</surname><given-names>A</given-names></name><name><surname>Greiner</surname><given-names>RA</given-names></name><name><surname>Autenried</surname><given-names>P</given-names></name><etal/></person-group><year>1993</year><article-title>Mice devoid of PrP are resistant to scrapie.</article-title><source>Cell</source><volume>73</volume><fpage>1339</fpage><lpage>1347</lpage><pub-id pub-id-type="pmid">8100741</pub-id></mixed-citation></ref><ref id="pone.0006707-Brandner1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandner</surname><given-names>S</given-names></name><name><surname>Isenmann</surname><given-names>S</given-names></name><name><surname>Raeber</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Sailer</surname><given-names>A</given-names></name><etal/></person-group><year>1996</year><article-title>Normal host prion protein necessary for scrapie-induced neurotoxicity.</article-title><source>Nature</source><volume>379</volume><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">8552188</pub-id></mixed-citation></ref><ref id="pone.0006707-Beler2"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;eler</surname><given-names>HR</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>Y</given-names></name><name><surname>Bluethmann</surname><given-names>H</given-names></name><name><surname>Lipp</surname><given-names>HP</given-names></name><etal/></person-group><year>1992</year><article-title>Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.</article-title><source>Nature</source><volume>356</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">1373228</pub-id></mixed-citation></ref><ref id="pone.0006707-Nazor1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazor</surname><given-names>KE</given-names></name><name><surname>Seward</surname><given-names>T</given-names></name><name><surname>Telling</surname><given-names>GC</given-names></name></person-group><year>2007</year><article-title>Motor behavioral and neuropathological deficits in mice deficient for normal prion protein expression.</article-title><source>Biochim Biophys Acta</source><volume>1772</volume><fpage>645</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">17531449</pub-id></mixed-citation></ref><ref id="pone.0006707-Aguzzi1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Polymenidou</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Mammalian prion biology. One century of evolving concepts.</article-title><source>Cell</source><volume>116</volume><fpage>313</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">14744440</pub-id></mixed-citation></ref><ref id="pone.0006707-Shmerling1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmerling</surname><given-names>D</given-names></name><name><surname>Hegyi</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Blattler</surname><given-names>T</given-names></name><name><surname>Brandner</surname><given-names>S</given-names></name><etal/></person-group><year>1998</year><article-title>Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions.</article-title><source>Cell</source><volume>93</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">9568713</pub-id></mixed-citation></ref><ref id="pone.0006707-Baumann1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>F</given-names></name><name><surname>Tolnay</surname><given-names>M</given-names></name><name><surname>Brabeck</surname><given-names>C</given-names></name><name><surname>Pahnke</surname><given-names>J</given-names></name><name><surname>Kloz</surname><given-names>U</given-names></name><etal/></person-group><year>2007</year><article-title>Lethal recessive myelin toxicity of prion protein lacking its central domain.</article-title><source>EMBO J</source><volume>26</volume><fpage>538</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">17245436</pub-id></mixed-citation></ref><ref id="pone.0006707-Li1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>H</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Roth</surname><given-names>K</given-names></name><name><surname>Chiesa</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x02013;125.</article-title><source>EMBO J</source><volume>26</volume><fpage>548</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">17245437</pub-id></mixed-citation></ref><ref id="pone.0006707-Wuthrich1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuthrich</surname><given-names>K</given-names></name><name><surname>Riek</surname><given-names>R</given-names></name></person-group><year>2001</year><article-title>Three-dimensional structures of prion proteins.</article-title><source>Adv Protein Chem</source><volume>57</volume><fpage>55</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11447697</pub-id></mixed-citation></ref><ref id="pone.0006707-Rossi1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Cozzio</surname><given-names>A</given-names></name><name><surname>Flechsig</surname><given-names>E</given-names></name><name><surname>Klein</surname><given-names>MA</given-names></name><name><surname>Rulicke</surname><given-names>T</given-names></name><etal/></person-group><year>2001</year><article-title>Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain.</article-title><source>Embo J</source><volume>20</volume><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">11179214</pub-id></mixed-citation></ref><ref id="pone.0006707-Moore1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>IY</given-names></name><name><surname>Silverman</surname><given-names>GL</given-names></name><name><surname>Harrison</surname><given-names>PM</given-names></name><name><surname>Strome</surname><given-names>R</given-names></name><etal/></person-group><year>1999</year><article-title>Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel</article-title><source>J Mol Biol</source><volume>292</volume><fpage>797</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">10525406</pub-id></mixed-citation></ref><ref id="pone.0006707-Weissmann1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>C</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><year>1999</year><article-title>Perspectives: neurobiology. PrP's double causes trouble.</article-title><source>Science</source><volume>286</volume><fpage>914</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">10577243</pub-id></mixed-citation></ref><ref id="pone.0006707-Sakaguchi1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Katamine</surname><given-names>S</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Moriuchi</surname><given-names>R</given-names></name><name><surname>Shigematsu</surname><given-names>K</given-names></name><etal/></person-group><year>1996</year><article-title>Loss of Cerebellar Purkinje Cells in Aged Mice Homozygous For a Disrupted Prp Gene.</article-title><source>Nature</source><volume>380</volume><fpage>528</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">8606772</pub-id></mixed-citation></ref><ref id="pone.0006707-Nishida1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Tremblay</surname><given-names>P</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Shigematsu</surname><given-names>K</given-names></name><name><surname>Shirabe</surname><given-names>S</given-names></name><etal/></person-group><year>1999</year><article-title>A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination.</article-title><source>Lab Invest</source><volume>79</volume><fpage>689</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">10378511</pub-id></mixed-citation></ref><ref id="pone.0006707-Yamaguchi1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Shigematsu</surname><given-names>K</given-names></name><name><surname>Okimura</surname><given-names>N</given-names></name><name><surname>Katamine</surname><given-names>S</given-names></name></person-group><year>2004</year><article-title>Doppel-induced Purkinje cell death is stoichiometrically abrogated by prion protein.</article-title><source>Biochem Biophys Res Commun</source><volume>319</volume><fpage>1247</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">15194501</pub-id></mixed-citation></ref><ref id="pone.0006707-Moore2"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RC</given-names></name><name><surname>Mastrangelo</surname><given-names>P</given-names></name><name><surname>Bouzamondo</surname><given-names>E</given-names></name><name><surname>Heinrich</surname><given-names>C</given-names></name><name><surname>Legname</surname><given-names>G</given-names></name><etal/></person-group><year>2001</year><article-title>Doppel-induced cerebellar degeneration in transgenic mice.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>15288</fpage><lpage>15293</lpage><pub-id pub-id-type="pmid">11734625</pub-id></mixed-citation></ref><ref id="pone.0006707-Luhrs1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luhrs</surname><given-names>T</given-names></name><name><surname>Riek</surname><given-names>R</given-names></name><name><surname>Guntert</surname><given-names>P</given-names></name><name><surname>Wuthrich</surname><given-names>K</given-names></name></person-group><year>2003</year><article-title>NMR structure of the human doppel protein.</article-title><source>J Mol Biol</source><volume>326</volume><fpage>1549</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">12595265</pub-id></mixed-citation></ref><ref id="pone.0006707-Behrens1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>A</given-names></name><name><surname>Genoud</surname><given-names>N</given-names></name><name><surname>Naumann</surname><given-names>H</given-names></name><name><surname>Rulicke</surname><given-names>T</given-names></name><name><surname>Janett</surname><given-names>F</given-names></name><etal/></person-group><year>2002</year><article-title>Absence of the prion protein homologue Doppel causes male sterility.</article-title><source>EMBO J</source><volume>21</volume><fpage>3652</fpage><lpage>3658</lpage><pub-id pub-id-type="pmid">12110578</pub-id></mixed-citation></ref><ref id="pone.0006707-Moore3"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>IY</given-names></name><name><surname>Silverman</surname><given-names>GL</given-names></name><name><surname>Harrison</surname><given-names>PM</given-names></name><name><surname>Strome</surname><given-names>R</given-names></name><etal/></person-group><year>1999</year><article-title>Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel.</article-title><source>J Mol Biol</source><volume>292</volume><fpage>797</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">10525406</pub-id></mixed-citation></ref><ref id="pone.0006707-Li2"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>HM</given-names></name><name><surname>Stewart</surname><given-names>LR</given-names></name><name><surname>Roth</surname><given-names>KA</given-names></name><name><surname>Chiesa</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x02013;125.</article-title><source>Embo J</source><volume>26</volume><fpage>548</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">17245437</pub-id></mixed-citation></ref><ref id="pone.0006707-Yoshikawa1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>D</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Ishibashi</surname><given-names>D</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Okimura</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>Dominant-negative effects of the N-terminal half of prion protein on neurotoxicity of prion protein-like protein/doppel in mice.</article-title><source>J Biol Chem</source><volume>283</volume><fpage>24202</fpage><lpage>24211</lpage><pub-id pub-id-type="pmid">18562311</pub-id></mixed-citation></ref><ref id="pone.0006707-Fischer1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>R&#x000fc;licke</surname><given-names>T</given-names></name><name><surname>Raeber</surname><given-names>A</given-names></name><name><surname>Sailer</surname><given-names>A</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name><etal/></person-group><year>1996</year><article-title>Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.</article-title><source>EMBO J</source><volume>15</volume><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">8635458</pub-id></mixed-citation></ref><ref id="pone.0006707-Karapetyan1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karapetyan</surname><given-names>YE</given-names></name><name><surname>Saa</surname><given-names>P</given-names></name><name><surname>Mahal</surname><given-names>SP</given-names></name><name><surname>Sferrazza</surname><given-names>GF</given-names></name><name><surname>Sherman</surname><given-names>A</given-names></name><etal/></person-group><year>2009</year><article-title>Prion strain discrimination based on rapid in vivo amplification and analysis by the cell panel assay.</article-title><source>PLoS ONE</source><volume>4</volume><fpage>e5730</fpage><pub-id pub-id-type="pmid">19478942</pub-id></mixed-citation></ref><ref id="pone.0006707-MouilletRichard1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouillet-Richard</surname><given-names>S</given-names></name><name><surname>Ermonval</surname><given-names>M</given-names></name><name><surname>Chebassier</surname><given-names>C</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><etal/></person-group><year>2000</year><article-title>Signal transduction through prion protein.</article-title><source>Science</source><volume>289</volume><fpage>1925</fpage><lpage>1928</lpage><pub-id pub-id-type="pmid">10988071</pub-id></mixed-citation></ref><ref id="pone.0006707-Chen1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Mange</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Schachner</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival.</article-title><source>Mol Cell Neurosci</source><volume>22</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">12676532</pub-id></mixed-citation></ref><ref id="pone.0006707-Santuccione1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santuccione</surname><given-names>A</given-names></name><name><surname>Sytnyk</surname><given-names>V</given-names></name><name><surname>Leshchyns'ka</surname><given-names>I</given-names></name><name><surname>Schachner</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth.</article-title><source>J Cell Biol</source><volume>169</volume><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">15851519</pub-id></mixed-citation></ref><ref id="pone.0006707-Toni1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toni</surname><given-names>M</given-names></name><name><surname>Spisni</surname><given-names>E</given-names></name><name><surname>Griffoni</surname><given-names>C</given-names></name><name><surname>Santi</surname><given-names>S</given-names></name><name><surname>Riccio</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Cellular prion protein and caveolin-1 interaction in a neuronal cell line precedes fyn/erk 1/2 signal transduction.</article-title><source>J Biomed Biotechnol</source><volume>2006</volume><fpage>69469</fpage><pub-id pub-id-type="pmid">17489019</pub-id></mixed-citation></ref><ref id="pone.0006707-Polymenidou1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymenidou</surname><given-names>M</given-names></name><name><surname>Moos</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Sigurdson</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>YZ</given-names></name><etal/></person-group><year>2008</year><article-title>The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes.</article-title><source>PLoS ONE</source><volume>3</volume><fpage>e3872</fpage><pub-id pub-id-type="pmid">19060956</pub-id></mixed-citation></ref><ref id="pone.0006707-Chesebro1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>B</given-names></name><name><surname>Trifilo</surname><given-names>M</given-names></name><name><surname>Race</surname><given-names>R</given-names></name><name><surname>Meade-White</surname><given-names>K</given-names></name><name><surname>Teng</surname><given-names>C</given-names></name><etal/></person-group><year>2005</year><article-title>Anchorless prion protein results in infectious amyloid disease without clinical scrapie.</article-title><source>Science</source><volume>308</volume><fpage>1435</fpage><lpage>1439</lpage><pub-id pub-id-type="pmid">15933194</pub-id></mixed-citation></ref><ref id="pone.0006707-Radovanovic1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radovanovic</surname><given-names>I</given-names></name><name><surname>Braun</surname><given-names>N</given-names></name><name><surname>Giger</surname><given-names>OT</given-names></name><name><surname>Mertz</surname><given-names>K</given-names></name><name><surname>Miele</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Truncated prion protein and Doppel are myelinotoxic in the absence of oligodendrocytic PrPC.</article-title><source>J Neurosci</source><volume>25</volume><fpage>4879</fpage><lpage>4888</lpage><pub-id pub-id-type="pmid">15888663</pub-id></mixed-citation></ref><ref id="pone.0006707-Zahn1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Luhrs</surname><given-names>T</given-names></name><name><surname>Riek</surname><given-names>R</given-names></name><name><surname>von Schroetter</surname><given-names>C</given-names></name><etal/></person-group><year>2000</year><article-title>NMR solution structure of the human prion protein.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">10618385</pub-id></mixed-citation></ref><ref id="pone.0006707-Riek1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riek</surname><given-names>R</given-names></name><name><surname>Luhrs</surname><given-names>T</given-names></name></person-group><year>2003</year><article-title>Three-dimensional structures of the prion protein and its doppel.</article-title><source>Clin Lab Med</source><volume>23</volume><fpage>209</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">12733433</pub-id></mixed-citation></ref><ref id="pone.0006707-Radovanovic2"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radovanovic</surname><given-names>I</given-names></name><name><surname>Braun</surname><given-names>N</given-names></name><name><surname>Giger</surname><given-names>OT</given-names></name><name><surname>Mertz</surname><given-names>K</given-names></name><name><surname>Miele</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Truncated Prion Protein and Doppel Are Myelinotoxic in the Absence of Oligodendrocytic PrPC.</article-title><source>J Neurosci</source><volume>25</volume><fpage>4879</fpage><lpage>4888</lpage><pub-id pub-id-type="pmid">15888663</pub-id></mixed-citation></ref><ref id="pone.0006707-Chacon1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chacon</surname><given-names>MA</given-names></name><name><surname>Barria</surname><given-names>MI</given-names></name><name><surname>Lorca</surname><given-names>R</given-names></name><name><surname>Huidobro-Toro</surname><given-names>JP</given-names></name><name><surname>Inestrosa</surname><given-names>NC</given-names></name></person-group><year>2003</year><article-title>A human prion protein peptide (PrP(59&#x02013;91)) protects against copper neurotoxicity.</article-title><source>Mol Psychiatry</source><volume>8</volume><fpage>853</fpage><lpage>862, 835</lpage><pub-id pub-id-type="pmid">14515136</pub-id></mixed-citation></ref><ref id="pone.0006707-Drisaldi1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drisaldi</surname><given-names>B</given-names></name><name><surname>Coomaraswamy</surname><given-names>J</given-names></name><name><surname>Mastrangelo</surname><given-names>P</given-names></name><name><surname>Strome</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B' region.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>55443</fpage><lpage>55454</lpage><pub-id pub-id-type="pmid">15459186</pub-id></mixed-citation></ref><ref id="pone.0006707-Mitteregger1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitteregger</surname><given-names>G</given-names></name><name><surname>Vosko</surname><given-names>M</given-names></name><name><surname>Krebs</surname><given-names>B</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Kohlmannsperger</surname><given-names>V</given-names></name><etal/></person-group><year>2007</year><article-title>The role of the octarepeat region in neuroprotective function of the cellular prion protein.</article-title><source>Brain Pathol</source><volume>17</volume><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">17388948</pub-id></mixed-citation></ref><ref id="pone.0006707-VarelaNallar1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela-Nallar</surname><given-names>L</given-names></name><name><surname>Toledo</surname><given-names>EM</given-names></name><name><surname>Chacon</surname><given-names>MA</given-names></name><name><surname>Inestrosa</surname><given-names>NC</given-names></name></person-group><year>2006</year><article-title>The functional links between prion protein and copper.</article-title><source>Biol Res</source><volume>39</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16629163</pub-id></mixed-citation></ref><ref id="pone.0006707-Atarashi1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atarashi</surname><given-names>R</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Shigematsu</surname><given-names>K</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Deletion of N-terminal residues 23-88 from prion protein (PrP) abrogates the potential to rescue PrP-deficient mice from PrP-like protein/doppel-induced Neurodegeneration.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>28944</fpage><lpage>28949</lpage><pub-id pub-id-type="pmid">12759361</pub-id></mixed-citation></ref><ref id="pone.0006707-Drisaldi2"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drisaldi</surname><given-names>B</given-names></name><name><surname>Stewart</surname><given-names>RS</given-names></name><name><surname>Adles</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>LR</given-names></name><name><surname>Quaglio</surname><given-names>E</given-names></name><etal/></person-group><year>2003</year><article-title>Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>21732</fpage><lpage>21743</lpage><pub-id pub-id-type="pmid">12663673</pub-id></mixed-citation></ref><ref id="pone.0006707-Khosravani1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosravani</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tsutsui</surname><given-names>S</given-names></name><name><surname>Hameed</surname><given-names>S</given-names></name><name><surname>Altier</surname><given-names>C</given-names></name><etal/></person-group><year>2008</year><article-title>Prion protein attenuates excitotoxicity by inhibiting NMDA receptors.</article-title><source>J Gen Physiol</source><volume>131</volume><fpage>i5</fpage><pub-id pub-id-type="pmid">18504311</pub-id></mixed-citation></ref><ref id="pone.0006707-Mattei1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattei</surname><given-names>V</given-names></name><name><surname>Garofalo</surname><given-names>T</given-names></name><name><surname>Misasi</surname><given-names>R</given-names></name><name><surname>Circella</surname><given-names>A</given-names></name><name><surname>Manganelli</surname><given-names>V</given-names></name><etal/></person-group><year>2004</year><article-title>Prion protein is a component of the multimolecular signaling complex involved in T cell activation.</article-title><source>FEBS Lett</source><volume>560</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">14987990</pub-id></mixed-citation></ref><ref id="pone.0006707-MouilletRichard2"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouillet-Richard</surname><given-names>S</given-names></name><name><surname>Ermonval</surname><given-names>M</given-names></name><name><surname>Chebassier</surname><given-names>C</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><etal/></person-group><year>2000</year><article-title>Signal transduction through prion protein.</article-title><source>Science</source><volume>289</volume><fpage>1925</fpage><lpage>1928</lpage><pub-id pub-id-type="pmid">10988071</pub-id></mixed-citation></ref><ref id="pone.0006707-Solforosi1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solforosi</surname><given-names>L</given-names></name><name><surname>Criado</surname><given-names>JR</given-names></name><name><surname>McGavern</surname><given-names>DB</given-names></name><name><surname>Wirz</surname><given-names>S</given-names></name><name><surname>Sanchez-Alavez</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Cross-linking cellular prion protein triggers neuronal apoptosis in vivo.</article-title><source>Science</source><volume>303</volume><fpage>1514</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">14752167</pub-id></mixed-citation></ref><ref id="pone.0006707-Behrens2"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>A</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>Small is not beautiful: antagonizing functions for the prion protein PrP(C) and its homologue Dpl.</article-title><source>Trends Neurosci</source><volume>25</volume><fpage>150</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">11852147</pub-id></mixed-citation></ref><ref id="pone.0006707-Zanata1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanata</surname><given-names>SM</given-names></name><name><surname>Lopes</surname><given-names>MH</given-names></name><name><surname>Mercadante</surname><given-names>AF</given-names></name><name><surname>Hajj</surname><given-names>GN</given-names></name><name><surname>Chiarini</surname><given-names>LB</given-names></name><etal/></person-group><year>2002</year><article-title>Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection.</article-title><source>Embo J</source><volume>21</volume><fpage>3307</fpage><lpage>3316</lpage><pub-id pub-id-type="pmid">12093732</pub-id></mixed-citation></ref><ref id="pone.0006707-Warner1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>RG</given-names></name><name><surname>Hundt</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Turnbull</surname><given-names>JE</given-names></name></person-group><year>2002</year><article-title>Identification of the heparan sulfate binding sites in the cellular prion protein.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>18421</fpage><lpage>18430</lpage><pub-id pub-id-type="pmid">11882649</pub-id></mixed-citation></ref><ref id="pone.0006707-Trifilo1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trifilo</surname><given-names>MJ</given-names></name><name><surname>Yajima</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Dalton</surname><given-names>N</given-names></name><name><surname>Peterson</surname><given-names>KL</given-names></name><etal/></person-group><year>2006</year><article-title>Prion-induced amyloid heart disease with high blood infectivity in transgenic mice.</article-title><source>Science</source><volume>313</volume><fpage>94</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">16825571</pub-id></mixed-citation></ref><ref id="pone.0006707-Trifilo2"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trifilo</surname><given-names>MJ</given-names></name><name><surname>Sanchez-Alavez</surname><given-names>M</given-names></name><name><surname>Solforosi</surname><given-names>L</given-names></name><name><surname>Bernard-Trifilo</surname><given-names>J</given-names></name><name><surname>Kunz</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>Scrapie-induced defects in learning and memory of transgenic mice expressing anchorless prion protein are associated with alterations in the gamma aminobutyric acid-ergic pathway.</article-title><source>J Virol</source><volume>82</volume><fpage>9890</fpage><lpage>9899</lpage><pub-id pub-id-type="pmid">18667494</pub-id></mixed-citation></ref><ref id="pone.0006707-Aguzzi2"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Cell biology. Prion toxicity: all sail and no anchor.</article-title><source>Science</source><volume>308</volume><fpage>1420</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">15933188</pub-id></mixed-citation></ref><ref id="pone.0006707-Aguzzi3"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><year>2003</year><article-title>Games played by rogue proteins in prion disorders and Alzheimer's disease.</article-title><source>Science</source><volume>302</volume><fpage>814</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">14593165</pub-id></mixed-citation></ref><ref id="pone.0006707-Griffiths1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>I</given-names></name><name><surname>Klugmann</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Yool</surname><given-names>D</given-names></name><name><surname>Thomson</surname><given-names>C</given-names></name><etal/></person-group><year>1998</year><article-title>Axonal swellings and degeneration in mice lacking the major proteolipid of myelin.</article-title><source>Science</source><volume>280</volume><fpage>1610</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">9616125</pub-id></mixed-citation></ref><ref id="pone.0006707-Rulicke1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rulicke</surname><given-names>T</given-names></name></person-group><year>2004</year><article-title>Pronuclear microinjection of mouse zygotes.</article-title><source>Methods Mol Biol</source><volume>254</volume><fpage>165</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15041762</pub-id></mixed-citation></ref><ref id="pone.0006707-Naslavsky1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naslavsky</surname><given-names>N</given-names></name><name><surname>Stein</surname><given-names>R</given-names></name><name><surname>Yanai</surname><given-names>A</given-names></name><name><surname>Friedlander</surname><given-names>G</given-names></name><name><surname>Taraboulos</surname><given-names>A</given-names></name></person-group><year>1997</year><article-title>Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform.</article-title><source>J Biol Chem</source><volume>272</volume><fpage>6324</fpage><lpage>6331</lpage><pub-id pub-id-type="pmid">9045652</pub-id></mixed-citation></ref><ref id="pone.0006707-Hornemann1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornemann</surname><given-names>S</given-names></name><name><surname>Schorn</surname><given-names>C</given-names></name><name><surname>Wuthrich</surname><given-names>K</given-names></name></person-group><year>2004</year><article-title>NMR structure of the bovine prion protein isolated from healthy calf brains.</article-title><source>EMBO Rep</source><volume>5</volume><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">15568016</pub-id></mixed-citation></ref><ref id="pone.0006707-Polymenidou2"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymenidou</surname><given-names>M</given-names></name><name><surname>Trusheim</surname><given-names>H</given-names></name><name><surname>Stallmach</surname><given-names>L</given-names></name><name><surname>Moos</surname><given-names>R</given-names></name><name><surname>Julius</surname><given-names>C</given-names></name><etal/></person-group><year>2008</year><article-title>Canine MDCK cell lines are refractory to infection with human and mouse prions.</article-title><source>Vaccine</source><volume>26</volume><fpage>2601</fpage><lpage>2614</lpage><pub-id pub-id-type="pmid">18423803</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>FB was a postdoctoral fellow of the Deutsche Forschungsgemeinschaft (BA2257/1-1). This work was supported by the EU Commission (TSEUR to AA, and APOPIS to AA and FB). BA2257/1-1 Deutsche Forschungsgemeinschaft DFG <ext-link ext-link-type="uri" xlink:href="http://www.dfg.de">http://www.dfg.de</ext-link> TSEUR An integrated immunological and cellular strategy for sensitive TSE diagnosis and strain discrimination EU Comission <ext-link ext-link-type="uri" xlink:href="http://cordis.europa.eu/fetch?CALLER=FP6_PROJ&#x00026;ACTION=D&#x00026;DOC=1148&#x00026;CAT=PROJ&#x00026;QUERY=1170700748402&#x00026;RCN=78399">http://cordis.europa.eu/fetch?CALLER=FP6_PROJ&#x00026;ACTION=D&#x00026;DOC=1148&#x00026;CAT=PROJ&#x00026;QUERY=1170700748402&#x00026;RCN=78399</ext-link> APOPIS An Integrated Project funded by the EU under the SIXTH FRAMEWORK PROGRAMME,PRIORITY: LIFE SCIENCES FOR HEALTH, Contract No. LSHM-CT-2003-503330 EU Comission <ext-link ext-link-type="uri" xlink:href="http://www.verum-foundation.de/apopis/">http://www.verum-foundation.de/apopis/</ext-link> The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>